source name	characteristics[organism]	characteristics[organism part]	characteristics[age]	characteristics[sex]	characteristics[disease]	characteristics[ancestry category]	characteristics[cell type]	characteristics[cell line]	characteristics[compound]	characteristics[enrichment process]	characteristics[biological replicate]	material type	assay name	technology type	comment[data file]	comment[file uri]	comment[technical replicate]	comment[fraction identifier]	comment[label]	comment[cleavage agent details]	comment[instrument]	comment[modification parameters]	comment[modification parameters]	comment[modification parameters]	comment[dissociation method]	comment[collision energy]	comment[precursor mass tolerance]	comment[fragment mass tolerance]	factor value[cell line]	factor value[compound]
Sample 1	Homo sapiens	B lymphocyte	38Y	male	Transformed follicular lymphoma	Caucasian	B lymphocyte	SU-DHL-4	no compound	glycosylation	1	cell	run 1	proteomic profiling by mass spectrometry	UM_2009_1432a-SUDHL4.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1432a-SUDHL4.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SU-DHL-4	no compound
Sample 1	Homo sapiens	B lymphocyte	38Y	male	Transformed follicular lymphoma	Caucasian	B lymphocyte	SU-DHL-4	no compound	glycosylation	1	cell	run 2	proteomic profiling by mass spectrometry	UM_2009_1432b-SUDHL4.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1432b-SUDHL4.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SU-DHL-4	no compound
Sample 1	Homo sapiens	B lymphocyte	38Y	male	Transformed follicular lymphoma	Caucasian	B lymphocyte	SU-DHL-4	no compound	glycosylation	1	cell	run 3	proteomic profiling by mass spectrometry	UM_2009_1432c-SUDHL4.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1432c-SUDHL4.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SU-DHL-4	no compound
Sample 2	Homo sapiens	thyroid	71Y	male	Classical Hodgkin lymphoma	not available	not available	KMH2	no compound	glycosylation	1	cell	run 4	proteomic profiling by mass spectrometry	UM_2009_1433a-KMH2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1433a-KMH2.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMH2	no compound
Sample 2	Homo sapiens	thyroid	71Y	male	Classical Hodgkin lymphoma	not available	not available	KMH2	no compound	glycosylation	1	cell	run 5	proteomic profiling by mass spectrometry	UM_2009_1433b-KMH2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1433b-KMH2.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMH2	no compound
Sample 2	Homo sapiens	thyroid	71Y	male	Classical Hodgkin lymphoma	not available	not available	KMH2	no compound	glycosylation	1	cell	run 6	proteomic profiling by mass spectrometry	UM_2009_1433c-KMH2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1433c-KMH2.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMH2	no compound
Sample 3	Homo sapiens	lymphoblast	38Y	male	Transformed follicular lymphoma	Caucasian	B lymphocyte	SU-DHL-4	no compound	glycosylation	2	cell	run 7	proteomic profiling by mass spectrometry	UM_2009_1603_a-SUDHL4.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1603_a-SUDHL4.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SU-DHL-4	no compound
Sample 3	Homo sapiens	lymphoblast	38Y	male	Transformed follicular lymphoma	Caucasian	B lymphocyte	SU-DHL-4	no compound	glycosylation	2	cell	run 8	proteomic profiling by mass spectrometry	UM_2009_1603_b-SUDHL4.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1603_b-SUDHL4.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SU-DHL-4	no compound
Sample 3	Homo sapiens	lymphoblast	38Y	male	Transformed follicular lymphoma	Caucasian	B lymphocyte	SU-DHL-4	no compound	glycosylation	2	cell	run 9	proteomic profiling by mass spectrometry	UM_2009_1603_c-SUDHL4.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1603_c-SUDHL4.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SU-DHL-4	no compound
Sample 4	Homo sapiens	thyroid	71Y	male	Classical Hodgkin lymphoma	not available	not available	KMH2	no compound	glycosylation	2	cell	run 10	proteomic profiling by mass spectrometry	UM_2009_1604_a-KMH2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1604_a-KMH2.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMH2	no compound
Sample 4	Homo sapiens	thyroid	71Y	male	Classical Hodgkin lymphoma	not available	not available	KMH2	no compound	glycosylation	2	cell	run 11	proteomic profiling by mass spectrometry	UM_2009_1604_b-KMH2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1604_b-KMH2.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMH2	no compound
Sample 4	Homo sapiens	thyroid	71Y	male	Classical Hodgkin lymphoma	not available	not available	KMH2	no compound	glycosylation	2	cell	run 12	proteomic profiling by mass spectrometry	UM_2009_1604_c-KMH2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1604_c-KMH2.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMH2	no compound
Sample 5	Homo sapiens	thyroid	71Y	male	Classical Hodgkin lymphoma	not available	not available	KMH2	no compound	glycosylation	3	cell	run 13	proteomic profiling by mass spectrometry	UM_2009_1778_a-KMH2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1778_a-KMH2.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMH2	no compound
Sample 5	Homo sapiens	thyroid	71Y	male	Classical Hodgkin lymphoma	not available	not available	KMH2	no compound	glycosylation	3	cell	run 14	proteomic profiling by mass spectrometry	UM_2009_1778_b-KMH2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1778_b-KMH2.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMH2	no compound
Sample 5	Homo sapiens	thyroid	71Y	male	Classical Hodgkin lymphoma	not available	not available	KMH2	no compound	glycosylation	3	cell	run 15	proteomic profiling by mass spectrometry	UM_2009_1778_c-KMH2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_1778_c-KMH2.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMH2	no compound
Sample 6	Homo sapiens	lymphoblast	38Y	male	Transformed follicular lymphoma	Caucasian	B lymphocyte	SU-DHL-4	no compound	glycosylation	3	cell	run 16	proteomic profiling by mass spectrometry	UM_2009_a_1383-SUDHL4.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_a_1383-SUDHL4.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SU-DHL-4	no compound
Sample 6	Homo sapiens	lymphoblast	38Y	male	Transformed follicular lymphoma	Caucasian	B lymphocyte	SU-DHL-4	no compound	glycosylation	3	cell	run 17	proteomic profiling by mass spectrometry	UM_2009_A_2098_a1-SUDHL1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2098_a1-SUDHL1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SU-DHL-4	no compound
Sample 6	Homo sapiens	lymphoblast	38Y	male	Transformed follicular lymphoma	Caucasian	B lymphocyte	SU-DHL-4	no compound	glycosylation	3	cell	run 18	proteomic profiling by mass spectrometry	UM_2009_A_2098_a2-SUDHL1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2098_a2-SUDHL1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SU-DHL-4	no compound
Sample 7	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	no compound	glycosylation	1	cell	run 19	proteomic profiling by mass spectrometry	UM_2009_A_2098_a3-SUDHL1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2098_a3-SUDHL1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	no compound
Sample 7	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	no compound	glycosylation	1	cell	run 20	proteomic profiling by mass spectrometry	UM_2009_A_2099_a1-MEDB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2099_a1-MEDB1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	no compound
Sample 7	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	no compound	glycosylation	1	cell	run 21	proteomic profiling by mass spectrometry	UM_2009_A_2099_a2-MEDB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2099_a2-MEDB1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	no compound
Sample 8	Homo sapiens	lymphoblast	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B lymphocyte	Med-B1	no compound	glycosylation	1	cell	run 22	proteomic profiling by mass spectrometry	UM_2009_A_2099_a3-MEDB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2099_a3-MEDB1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Med-B1	no compound
Sample 8	Homo sapiens	lymphoblast	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B lymphocyte	Med-B1	no compound	glycosylation	1	cell	run 23	proteomic profiling by mass spectrometry	UM_2009_A_2100_a1-DEL.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2100_a1-DEL.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Med-B1	no compound
Sample 8	Homo sapiens	lymphoblast	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B lymphocyte	Med-B1	no compound	glycosylation	1	cell	run 24	proteomic profiling by mass spectrometry	UM_2009_A_2100_a2-DEL.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2100_a2-DEL.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Med-B1	no compound
Sample 9	Homo sapiens	not available	not available	not available	Anaplastic large cell lymphoma	not available	not available	DEL	no compound	glycosylation	1	cell	run 25	proteomic profiling by mass spectrometry	UM_2009_A_2100_a3-DEL.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2100_a3-DEL.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEL	no compound
Sample 9	Homo sapiens	not available	not available	not available	Anaplastic large cell lymphoma	not available	not available	DEL	no compound	glycosylation	1	cell	run 26	proteomic profiling by mass spectrometry	UM_2009_A_2233_a1-DEL.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2233_a1-DEL.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEL	no compound
Sample 9	Homo sapiens	not available	not available	not available	Anaplastic large cell lymphoma	not available	not available	DEL	no compound	glycosylation	1	cell	run 27	proteomic profiling by mass spectrometry	UM_2009_A_2233_a2-DEL.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2233_a2-DEL.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEL	no compound
Sample 10	Homo sapiens	not available	not available	not available	Anaplastic large cell lymphoma	not available	not available	DEL	no compound	glycosylation	2	cell	run 28	proteomic profiling by mass spectrometry	UM_2009_A_2233_a3-DEL.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2233_a3-DEL.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEL	no compound
Sample 10	Homo sapiens	not available	not available	not available	Anaplastic large cell lymphoma	not available	not available	DEL	no compound	glycosylation	2	cell	run 29	proteomic profiling by mass spectrometry	UM_2009_A_2234_a1-KARPAS1106P.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2234_a1-KARPAS1106P.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEL	no compound
Sample 10	Homo sapiens	not available	not available	not available	Anaplastic large cell lymphoma	not available	not available	DEL	no compound	glycosylation	2	cell	run 30	proteomic profiling by mass spectrometry	UM_2009_A_2234_a2-KARPAS1106P.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2234_a2-KARPAS1106P.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEL	no compound
Sample 11	Homo sapiens	Blood	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B cell lymphoma	Karpas 1106P	no compound	glycosylation	1	cell	run 31	proteomic profiling by mass spectrometry	UM_2009_A_2234_a3-KARPAS1106P.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2234_a3-KARPAS1106P.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 1106P	no compound
Sample 11	Homo sapiens	Blood	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B cell lymphoma	Karpas 1106P	no compound	glycosylation	1	cell	run 32	proteomic profiling by mass spectrometry	UM_2009_A_2479_a1-DEL.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2479_a1-DEL.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 1106P	no compound
Sample 11	Homo sapiens	Blood	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B cell lymphoma	Karpas 1106P	no compound	glycosylation	1	cell	run 33	proteomic profiling by mass spectrometry	UM_2009_A_2479_a2-DEL.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2479_a2-DEL.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 1106P	no compound
Sample 12	Homo sapiens	not available	not available	not available	Anaplastic large cell lymphoma	not available	not available	DEL	no compound	glycosylation	3	cell	run 34	proteomic profiling by mass spectrometry	UM_2009_A_2479_a3-DEL.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2479_a3-DEL.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEL	no compound
Sample 12	Homo sapiens	not available	not available	not available	Anaplastic large cell lymphoma	not available	not available	DEL	no compound	glycosylation	3	cell	run 35	proteomic profiling by mass spectrometry	UM_2009_A_2544_a1-SUDHL1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2544_a1-SUDHL1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEL	no compound
Sample 12	Homo sapiens	not available	not available	not available	Anaplastic large cell lymphoma	not available	not available	DEL	no compound	glycosylation	3	cell	run 36	proteomic profiling by mass spectrometry	UM_2009_A_2544_a2-SUDHL1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2544_a2-SUDHL1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEL	no compound
Sample 13	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	no compound	glycosylation	2	cell	run 37	proteomic profiling by mass spectrometry	UM_2009_A_2544_a3-SUDHL1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2544_a3-SUDHL1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	no compound
Sample 13	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	no compound	glycosylation	2	cell	run 38	proteomic profiling by mass spectrometry	UM_2009_A_2561_a1-L428.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2561_a1-L428.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	no compound
Sample 13	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	no compound	glycosylation	2	cell	run 39	proteomic profiling by mass spectrometry	UM_2009_A_2561_a2-L428.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2561_a2-L428.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	no compound
Sample 14	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	not available	L428	no compound	glycosylation	1	cell	run 40	proteomic profiling by mass spectrometry	UM_2009_A_2561_a3-L428.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2561_a3-L428.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L428	no compound
Sample 14	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	not available	L428	no compound	glycosylation	1	cell	run 41	proteomic profiling by mass spectrometry	UM_2009_A_2562_a1-MEDB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2562_a1-MEDB1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L428	no compound
Sample 14	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	not available	L428	no compound	glycosylation	1	cell	run 42	proteomic profiling by mass spectrometry	UM_2009_A_2562_a2-MEDB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2562_a2-MEDB1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L428	no compound
Sample 15	Homo sapiens	lymphoblast	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B lymphocyte	Med-B1	no compound	glycosylation	2	cell	run 43	proteomic profiling by mass spectrometry	UM_2009_A_2562_a3-MEDB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2562_a3-MEDB1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Med-B1	no compound
Sample 15	Homo sapiens	lymphoblast	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B lymphocyte	Med-B1	no compound	glycosylation	2	cell	run 44	proteomic profiling by mass spectrometry	UM_2009_A_2677_a1-SUDHL1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2677_a1-SUDHL1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Med-B1	no compound
Sample 15	Homo sapiens	lymphoblast	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B lymphocyte	Med-B1	no compound	glycosylation	2	cell	run 45	proteomic profiling by mass spectrometry	UM_2009_A_2677_a2-SUDHL1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2677_a2-SUDHL1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Med-B1	no compound
Sample 16	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	no compound	glycosylation	3	cell	run 46	proteomic profiling by mass spectrometry	UM_2009_A_2677_a3-SUDHL1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2677_a3-SUDHL1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	no compound
Sample 16	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	no compound	glycosylation	3	cell	run 47	proteomic profiling by mass spectrometry	UM_2009_A_2678_a1-OCILY2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2678_a1-OCILY2.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	no compound
Sample 16	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	no compound	glycosylation	3	cell	run 48	proteomic profiling by mass spectrometry	UM_2009_A_2678_a2-OCILY2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2678_a2-OCILY2.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	no compound
Sample 17	Homo sapiens	lymph node	not available	not available	Diffuse large B-cell lymphoma	not available	not available	OCI-Ly2	no compound	glycosylation	1	cell	run 49	proteomic profiling by mass spectrometry	UM_2009_A_2678_a3-OCILY2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2678_a3-OCILY2.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly2	no compound
Sample 17	Homo sapiens	lymph node	not available	not available	Diffuse large B-cell lymphoma	not available	not available	OCI-Ly2	no compound	glycosylation	1	cell	run 50	proteomic profiling by mass spectrometry	UM_2009_A_2764_a1-L428.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2764_a1-L428.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly2	no compound
Sample 17	Homo sapiens	lymph node	not available	not available	Diffuse large B-cell lymphoma	not available	not available	OCI-Ly2	no compound	glycosylation	1	cell	run 51	proteomic profiling by mass spectrometry	UM_2009_A_2764_a2-L428.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2764_a2-L428.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly2	no compound
Sample 18	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	not available	L428	no compound	glycosylation	2	cell	run 52	proteomic profiling by mass spectrometry	UM_2009_A_2764_a3-L428.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2764_a3-L428.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L428	no compound
Sample 18	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	not available	L428	no compound	glycosylation	2	cell	run 53	proteomic profiling by mass spectrometry	UM_2009_A_2765_a1-MEDB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2765_a1-MEDB1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L428	no compound
Sample 18	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	not available	L428	no compound	glycosylation	2	cell	run 54	proteomic profiling by mass spectrometry	UM_2009_A_2765_a2-MEDB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2765_a2-MEDB1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L428	no compound
Sample 19	Homo sapiens	B lymphocyte	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B lymphocyte	Med-B1	no compound	glycosylation	3	cell	run 55	proteomic profiling by mass spectrometry	UM_2009_A_2765_a3-MEDB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2765_a3-MEDB1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Med-B1	no compound
Sample 19	Homo sapiens	B lymphocyte	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B lymphocyte	Med-B1	no compound	glycosylation	3	cell	run 56	proteomic profiling by mass spectrometry	UM_2009_A_2823_a1-L428.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2823_a1-L428.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Med-B1	no compound
Sample 19	Homo sapiens	B lymphocyte	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B lymphocyte	Med-B1	no compound	glycosylation	3	cell	run 57	proteomic profiling by mass spectrometry	UM_2009_A_2823_a2-L428.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2823_a2-L428.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Med-B1	no compound
Sample 20	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	not available	L428	no compound	glycosylation	3	cell	run 58	proteomic profiling by mass spectrometry	UM_2009_A_2823_a3-L428.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2823_a3-L428.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L428	no compound
Sample 20	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	not available	L428	no compound	glycosylation	3	cell	run 59	proteomic profiling by mass spectrometry	UM_2009_A_2824_a1-KARPAS1106P.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2824_a1-KARPAS1106P.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L428	no compound
Sample 20	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	not available	L428	no compound	glycosylation	3	cell	run 60	proteomic profiling by mass spectrometry	UM_2009_A_2824_a2-KARPAS1106P.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2824_a2-KARPAS1106P.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L428	no compound
Sample 21	Homo sapiens	Blood	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B cell lymphoma	Karpas 1106P	no compound	glycosylation	2	cell	run 61	proteomic profiling by mass spectrometry	UM_2009_A_2824_a3-KARPAS1106P.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2824_a3-KARPAS1106P.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 1106P	no compound
Sample 21	Homo sapiens	Blood	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B cell lymphoma	Karpas 1106P	no compound	glycosylation	2	cell	run 62	proteomic profiling by mass spectrometry	UM_2009_A_2881_a1-KARPAS1106P.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2881_a1-KARPAS1106P.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 1106P	no compound
Sample 21	Homo sapiens	Blood	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B cell lymphoma	Karpas 1106P	no compound	glycosylation	2	cell	run 63	proteomic profiling by mass spectrometry	UM_2009_A_2881_a2-KARPAS1106P.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2881_a2-KARPAS1106P.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 1106P	no compound
Sample 22	Homo sapiens	Blood	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B cell lymphoma	Karpas 1106P	no compound	glycosylation	3	cell	run 64	proteomic profiling by mass spectrometry	UM_2009_A_2881_a3-KARPAS1106P.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2881_a3-KARPAS1106P.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 1106P	no compound
Sample 22	Homo sapiens	Blood	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B cell lymphoma	Karpas 1106P	no compound	glycosylation	3	cell	run 65	proteomic profiling by mass spectrometry	UM_2009_A_2914_a1-NCEB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2914_a1-NCEB1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 1106P	no compound
Sample 22	Homo sapiens	Blood	not available	not available	Primary mediastinal large B-cell lymphoma	not available	B cell lymphoma	Karpas 1106P	no compound	glycosylation	3	cell	run 66	proteomic profiling by mass spectrometry	UM_2009_A_2914_a2-NCEB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2914_a2-NCEB1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 1106P	no compound
Sample 23	Homo sapiens	peripheral blood	57Y	not available	lymphoma	not available	lymphoblast	NCEB-1	no compound	glycosylation	1	cell	run 67	proteomic profiling by mass spectrometry	UM_2009_A_2914_a3-NCEB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2914_a3-NCEB1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NCEB-1	no compound
Sample 23	Homo sapiens	peripheral blood	57Y	not available	lymphoma	not available	lymphoblast	NCEB-1	no compound	glycosylation	1	cell	run 68	proteomic profiling by mass spectrometry	UM_2009_A_2915_a1-FL218.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2915_a1-FL218.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NCEB-1	no compound
Sample 23	Homo sapiens	peripheral blood	57Y	not available	lymphoma	not available	lymphoblast	NCEB-1	no compound	glycosylation	1	cell	run 69	proteomic profiling by mass spectrometry	UM_2009_A_2915_a2-FL218.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2915_a2-FL218.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NCEB-1	no compound
Sample 24	Homo sapiens	lymphoblast	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-218	no compound	glycosylation	1	cell	run 70	proteomic profiling by mass spectrometry	UM_2009_A_2915_a3-FL218.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2915_a3-FL218.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-218	no compound
Sample 24	Homo sapiens	lymphoblast	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-218	no compound	glycosylation	1	cell	run 71	proteomic profiling by mass spectrometry	UM_2009_A_2916_a1-FL218.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2916_a1-FL218.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-218	no compound
Sample 24	Homo sapiens	lymphoblast	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-218	no compound	glycosylation	1	cell	run 72	proteomic profiling by mass spectrometry	UM_2009_A_2916_a2-FL218.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2916_a2-FL218.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-218	no compound
Sample 25	Homo sapiens	lymphoblast	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-218	no compound	glycosylation	2	cell	run 73	proteomic profiling by mass spectrometry	UM_2009_A_2916_a3-FL218.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2916_a3-FL218.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-218	no compound
Sample 25	Homo sapiens	lymphoblast	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-218	no compound	glycosylation	2	cell	run 74	proteomic profiling by mass spectrometry	UM_2009_A_2918_a1-OCILY2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2918_a1-OCILY2.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-218	no compound
Sample 25	Homo sapiens	lymphoblast	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-218	no compound	glycosylation	2	cell	run 75	proteomic profiling by mass spectrometry	UM_2009_A_2918_a2-OCILY2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2918_a2-OCILY2.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-218	no compound
Sample 26	Homo sapiens	lymph node	not available	not available	Diffuse large B-cell lymphoma	not available	not available	OCI-Ly2	no compound	glycosylation	2	cell	run 76	proteomic profiling by mass spectrometry	UM_2009_A_2918_a3-OCILY2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2918_a3-OCILY2.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly2	no compound
Sample 26	Homo sapiens	lymph node	not available	not available	Diffuse large B-cell lymphoma	not available	not available	OCI-Ly2	no compound	glycosylation	2	cell	run 77	proteomic profiling by mass spectrometry	UM_2009_A_2920_a1-NCEB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2920_a1-NCEB1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly2	no compound
Sample 26	Homo sapiens	lymph node	not available	not available	Diffuse large B-cell lymphoma	not available	not available	OCI-Ly2	no compound	glycosylation	2	cell	run 78	proteomic profiling by mass spectrometry	UM_2009_A_2920_a2-NCEB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2920_a2-NCEB1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly2	no compound
Sample 27	Homo sapiens	peripheral blood	57Y	not available	lymphoma	not available	lymphoblast	NCEB-1	no compound	glycosylation	2	cell	run 79	proteomic profiling by mass spectrometry	UM_2009_A_2920_a3-NCEB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_2920_a3-NCEB1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NCEB-1	no compound
Sample 27	Homo sapiens	peripheral blood	57Y	not available	lymphoma	not available	lymphoblast	NCEB-1	no compound	glycosylation	2	cell	run 80	proteomic profiling by mass spectrometry	UM_2009_A_3210_a1-RAMOS.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3210_a1-RAMOS.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NCEB-1	no compound
Sample 27	Homo sapiens	peripheral blood	57Y	not available	lymphoma	not available	lymphoblast	NCEB-1	no compound	glycosylation	2	cell	run 81	proteomic profiling by mass spectrometry	UM_2009_A_3210_a2-RAMOS.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3210_a2-RAMOS.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NCEB-1	no compound
Sample 28	Homo sapiens	lymphoblast	3Y	male	Burkitt's lymphoma (American)	Caucasian	B lymphocyte	Ramos	no compound	glycosylation	1	cell	run 82	proteomic profiling by mass spectrometry	UM_2009_A_3210_a3-RAMOS.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3210_a3-RAMOS.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Ramos	no compound
Sample 28	Homo sapiens	lymphoblast	3Y	male	Burkitt's lymphoma (American)	Caucasian	B lymphocyte	Ramos	no compound	glycosylation	1	cell	run 83	proteomic profiling by mass spectrometry	UM_2009_A_3240_a3-RAMOS.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3240_a3-RAMOS.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Ramos	no compound
Sample 28	Homo sapiens	lymphoblast	3Y	male	Burkitt's lymphoma (American)	Caucasian	B lymphocyte	Ramos	no compound	glycosylation	1	cell	run 84	proteomic profiling by mass spectrometry	UM_2009_A_3240_a4-RAMOS.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3240_a4-RAMOS.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Ramos	no compound
Sample 29	Homo sapiens	lymphoblast	3Y	male	Burkitt's lymphoma (American)	Caucasian	B lymphocyte	Ramos	no compound	glycosylation	2	cell	run 85	proteomic profiling by mass spectrometry	UM_2009_A_3240_a5-RAMOS.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3240_a5-RAMOS.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Ramos	no compound
Sample 29	Homo sapiens	lymphoblast	3Y	male	Burkitt's lymphoma (American)	Caucasian	B lymphocyte	Ramos	no compound	glycosylation	2	cell	run 86	proteomic profiling by mass spectrometry	UM_2009_A_3241_a1-DEV.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3241_a1-DEV.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Ramos	no compound
Sample 29	Homo sapiens	lymphoblast	3Y	male	Burkitt's lymphoma (American)	Caucasian	B lymphocyte	Ramos	no compound	glycosylation	2	cell	run 87	proteomic profiling by mass spectrometry	UM_2009_A_3241_a2-DEV.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3241_a2-DEV.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Ramos	no compound
Sample 30	Homo sapiens	lymphoblast	not available	not available	Nodular lymphocyte predominant Hodgkin lymphoma	not available	B lymphocyte	DEV	no compound	glycosylation	1	cell	run 88	proteomic profiling by mass spectrometry	UM_2009_A_3241_a3-DEV.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3241_a3-DEV.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEV	no compound
Sample 30	Homo sapiens	lymphoblast	not available	not available	Nodular lymphocyte predominant Hodgkin lymphoma	not available	B lymphocyte	DEV	no compound	glycosylation	1	cell	run 89	proteomic profiling by mass spectrometry	UM_2009_A_3242_a1-DEV.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3242_a1-DEV.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEV	no compound
Sample 30	Homo sapiens	lymphoblast	not available	not available	Nodular lymphocyte predominant Hodgkin lymphoma	not available	B lymphocyte	DEV	no compound	glycosylation	1	cell	run 90	proteomic profiling by mass spectrometry	UM_2009_A_3242_a2-DEV.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3242_a2-DEV.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEV	no compound
Sample 31	Homo sapiens	lymphoblast	not available	not available	Nodular lymphocyte predominant Hodgkin lymphoma	not available	B lymphocyte	DEV	no compound	glycosylation	2	cell	run 91	proteomic profiling by mass spectrometry	UM_2009_A_3242_a3-DEV.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3242_a3-DEV.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEV	no compound
Sample 31	Homo sapiens	lymphoblast	not available	not available	Nodular lymphocyte predominant Hodgkin lymphoma	not available	B lymphocyte	DEV	no compound	glycosylation	2	cell	run 92	proteomic profiling by mass spectrometry	UM_2009_A_3245_a1-NCEB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3245_a1-NCEB1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEV	no compound
Sample 31	Homo sapiens	lymphoblast	not available	not available	Nodular lymphocyte predominant Hodgkin lymphoma	not available	B lymphocyte	DEV	no compound	glycosylation	2	cell	run 93	proteomic profiling by mass spectrometry	UM_2009_A_3245_a2-NCEB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3245_a2-NCEB1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEV	no compound
Sample 32	Homo sapiens	peripheral blood	57Y	not available	lymphoma	not available	lymphoblast	NCEB-1	no compound	glycosylation	3	cell	run 94	proteomic profiling by mass spectrometry	UM_2009_A_3245_a3-NCEB1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3245_a3-NCEB1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NCEB-1	no compound
Sample 32	Homo sapiens	peripheral blood	57Y	not available	lymphoma	not available	lymphoblast	NCEB-1	no compound	glycosylation	3	cell	run 95	proteomic profiling by mass spectrometry	UM_2009_A_3385_a1-OCILY2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3385_a1-OCILY2.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NCEB-1	no compound
Sample 32	Homo sapiens	peripheral blood	57Y	not available	lymphoma	not available	lymphoblast	NCEB-1	no compound	glycosylation	3	cell	run 96	proteomic profiling by mass spectrometry	UM_2009_A_3385_a2-OCILY2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3385_a2-OCILY2.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NCEB-1	no compound
Sample 33	Homo sapiens	lymph node	not available	not available	Diffuse large B-cell lymphoma	not available	not available	OCI-Ly2	no compound	glycosylation	3	cell	run 97	proteomic profiling by mass spectrometry	UM_2009_A_3385_a3-OCILY2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3385_a3-OCILY2.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly2	no compound
Sample 33	Homo sapiens	lymph node	not available	not available	Diffuse large B-cell lymphoma	not available	not available	OCI-Ly2	no compound	glycosylation	3	cell	run 98	proteomic profiling by mass spectrometry	UM_2009_A_3447_a1-FL218.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3447_a1-FL218.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly2	no compound
Sample 33	Homo sapiens	lymph node	not available	not available	Diffuse large B-cell lymphoma	not available	not available	OCI-Ly2	no compound	glycosylation	3	cell	run 99	proteomic profiling by mass spectrometry	UM_2009_A_3447_a2-FL218.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3447_a2-FL218.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly2	no compound
Sample 34	Homo sapiens	lymphoblast	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-218	no compound	glycosylation	3	cell	run 100	proteomic profiling by mass spectrometry	UM_2009_A_3447_a3-FL218.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3447_a3-FL218.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-218	no compound
Sample 34	Homo sapiens	lymphoblast	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-218	no compound	glycosylation	3	cell	run 101	proteomic profiling by mass spectrometry	UM_2009_A_3494_a1-RAJI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3494_a1-RAJI.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-218	no compound
Sample 34	Homo sapiens	lymphoblast	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-218	no compound	glycosylation	3	cell	run 102	proteomic profiling by mass spectrometry	UM_2009_A_3494_a2-RAJI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3494_a2-RAJI.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-218	no compound
Sample 35	Homo sapiens	lymphoblast	11Y	male	Burkitt's lymphoma	Black	B lymphocyte	Raji	no compound	glycosylation	1	cell	run 103	proteomic profiling by mass spectrometry	UM_2009_A_3494_a3-RAJI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3494_a3-RAJI.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Raji	no compound
Sample 35	Homo sapiens	lymphoblast	11Y	male	Burkitt's lymphoma	Black	B lymphocyte	Raji	no compound	glycosylation	1	cell	run 104	proteomic profiling by mass spectrometry	UM_2009_A_3495_a1-RAJI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3495_a1-RAJI.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Raji	no compound
Sample 35	Homo sapiens	lymphoblast	11Y	male	Burkitt's lymphoma	Black	B lymphocyte	Raji	no compound	glycosylation	1	cell	run 105	proteomic profiling by mass spectrometry	UM_2009_A_3495_a2-RAJI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3495_a2-RAJI.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Raji	no compound
Sample 36	Homo sapiens	lymphoblast	11Y	male	Burkitt's lymphoma	Black	B lymphocyte	Raji	no compound	glycosylation	2	cell	run 106	proteomic profiling by mass spectrometry	UM_2009_A_3495_a3-RAJI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_A_3495_a3-RAJI.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Raji	no compound
Sample 36	Homo sapiens	lymphoblast	11Y	male	Burkitt's lymphoma	Black	B lymphocyte	Raji	no compound	glycosylation	2	cell	run 107	proteomic profiling by mass spectrometry	UM_2009_b_1383-SUDHL4.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_b_1383-SUDHL4.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Raji	no compound
Sample 36	Homo sapiens	lymphoblast	11Y	male	Burkitt's lymphoma	Black	B lymphocyte	Raji	no compound	glycosylation	2	cell	run 108	proteomic profiling by mass spectrometry	UM_2009_c_1383-SUDHL4.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2009_c_1383-SUDHL4.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Raji	no compound
Sample 37	Homo sapiens	Blood	not available	not available	Mantle cell lymphoma	not available	B lymphocyte	Granta 519	no compound	glycosylation	1	cell	run 109	proteomic profiling by mass spectrometry	UM_2010_A_0003_a1-GRANTA519.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2010_A_0003_a1-GRANTA519.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Granta 519	no compound
Sample 37	Homo sapiens	Blood	not available	not available	Mantle cell lymphoma	not available	B lymphocyte	Granta 519	no compound	glycosylation	1	cell	run 110	proteomic profiling by mass spectrometry	UM_2010_A_0003_a2-GRANTA519.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2010_A_0003_a2-GRANTA519.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Granta 519	no compound
Sample 37	Homo sapiens	Blood	not available	not available	Mantle cell lymphoma	not available	B lymphocyte	Granta 519	no compound	glycosylation	1	cell	run 111	proteomic profiling by mass spectrometry	UM_2010_A_0003_a3-GRANTA519.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_2010_A_0003_a3-GRANTA519.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Granta 519	no compound
Sample 38	Homo sapiens	lymphoblast	not available	not available	Nodular lymphocyte predominant Hodgkin lymphoma	not available	B lymphocyte	DEV	no compound	glycosylation	3	cell	run 112	proteomic profiling by mass spectrometry	UM_A_2009_3243_a1-DEV.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2009_3243_a1-DEV.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEV	no compound
Sample 38	Homo sapiens	lymphoblast	not available	not available	Nodular lymphocyte predominant Hodgkin lymphoma	not available	B lymphocyte	DEV	no compound	glycosylation	3	cell	run 113	proteomic profiling by mass spectrometry	UM_A_2009_3243_a2-DEV.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2009_3243_a2-DEV.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEV	no compound
Sample 38	Homo sapiens	lymphoblast	not available	not available	Nodular lymphocyte predominant Hodgkin lymphoma	not available	B lymphocyte	DEV	no compound	glycosylation	3	cell	run 114	proteomic profiling by mass spectrometry	UM_A_2009_3243_a3-DEV.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2009_3243_a3-DEV.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	DEV	no compound
Sample 39	Homo sapiens	lymphoblast	3Y	male	Burkitt's lymphoma (American)	Caucasian	B lymphocyte	Ramos	no compound	glycosylation	3	cell	run 115	proteomic profiling by mass spectrometry	UM_A_2009_3249_a1-RAMOS.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2009_3249_a1-RAMOS.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Ramos	no compound
Sample 39	Homo sapiens	lymphoblast	3Y	male	Burkitt's lymphoma (American)	Caucasian	B lymphocyte	Ramos	no compound	glycosylation	3	cell	run 116	proteomic profiling by mass spectrometry	UM_A_2009_3249_a2-RAMOS.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2009_3249_a2-RAMOS.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Ramos	no compound
Sample 39	Homo sapiens	lymphoblast	3Y	male	Burkitt's lymphoma (American)	Caucasian	B lymphocyte	Ramos	no compound	glycosylation	3	cell	run 117	proteomic profiling by mass spectrometry	UM_A_2009_3249_a3-RAMOS.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2009_3249_a3-RAMOS.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Ramos	no compound
Sample 40	Homo sapiens	lymphoblast	11Y	male	Burkitt's lymphoma	Black	B lymphocyte	Raji	no compound	glycosylation	3	cell	run 118	proteomic profiling by mass spectrometry	UM_A_2009_3388_a1-RAJI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2009_3388_a1-RAJI.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Raji	no compound
Sample 40	Homo sapiens	lymphoblast	11Y	male	Burkitt's lymphoma	Black	B lymphocyte	Raji	no compound	glycosylation	3	cell	run 119	proteomic profiling by mass spectrometry	UM_A_2009_3388_a2-RAJI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2009_3388_a2-RAJI.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Raji	no compound
Sample 40	Homo sapiens	lymphoblast	11Y	male	Burkitt's lymphoma	Black	B lymphocyte	Raji	no compound	glycosylation	3	cell	run 120	proteomic profiling by mass spectrometry	UM_A_2009_3388_a3-RAJI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2009_3388_a3-RAJI.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Raji	no compound
Sample 41	Homo sapiens	Blood	not available	not available	Mantle cell lymphoma	not available	B lymphocyte	Granta 519	no compound	glycosylation	2	cell	run 121	proteomic profiling by mass spectrometry	UM_A_2010_0004_a1-GRANTA519.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0004_a1-GRANTA519.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Granta 519	no compound
Sample 41	Homo sapiens	Blood	not available	not available	Mantle cell lymphoma	not available	B lymphocyte	Granta 519	no compound	glycosylation	2	cell	run 122	proteomic profiling by mass spectrometry	UM_A_2010_0004_a2-GRANTA519.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0004_a2-GRANTA519.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Granta 519	no compound
Sample 41	Homo sapiens	Blood	not available	not available	Mantle cell lymphoma	not available	B lymphocyte	Granta 519	no compound	glycosylation	2	cell	run 123	proteomic profiling by mass spectrometry	UM_A_2010_0004_a3-GRANTA519.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0004_a3-GRANTA519.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Granta 519	no compound
Sample 42	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	Lymphocyte	L1236	no compound	glycosylation	1	cell	run 124	proteomic profiling by mass spectrometry	UM_A_2010_0005_a1-L1236.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0005_a1-L1236.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L1236	no compound
Sample 42	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	Lymphocyte	L1236	no compound	glycosylation	1	cell	run 125	proteomic profiling by mass spectrometry	UM_A_2010_0005_a2-L1236.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0005_a2-L1236.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L1236	no compound
Sample 42	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	Lymphocyte	L1236	no compound	glycosylation	1	cell	run 126	proteomic profiling by mass spectrometry	UM_A_2010_0005_a3-L1236.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0005_a3-L1236.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L1236	no compound
Sample 43	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	Lymphocyte	L1236	no compound	glycosylation	2	cell	run 127	proteomic profiling by mass spectrometry	UM_A_2010_0007_a1-L1236.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0007_a1-L1236.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L1236	no compound
Sample 43	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	Lymphocyte	L1236	no compound	glycosylation	2	cell	run 128	proteomic profiling by mass spectrometry	UM_A_2010_0007_a2-L1236.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0007_a2-L1236.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L1236	no compound
Sample 43	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	Lymphocyte	L1236	no compound	glycosylation	2	cell	run 129	proteomic profiling by mass spectrometry	UM_A_2010_0007_a3-L1236.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0007_a3-L1236.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L1236	no compound
Sample 44	Homo sapiens	Blood	not available	not available	Mantle cell lymphoma	not available	B lymphocyte	Granta 519	no compound	glycosylation	3	cell	run 130	proteomic profiling by mass spectrometry	UM_A_2010_0012_a1-GRANTA519.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0012_a1-GRANTA519.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Granta 519	no compound
Sample 44	Homo sapiens	Blood	not available	not available	Mantle cell lymphoma	not available	B lymphocyte	Granta 519	no compound	glycosylation	3	cell	run 131	proteomic profiling by mass spectrometry	UM_A_2010_0012_a2-GRANTA519.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0012_a2-GRANTA519.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Granta 519	no compound
Sample 44	Homo sapiens	Blood	not available	not available	Mantle cell lymphoma	not available	B lymphocyte	Granta 519	no compound	glycosylation	3	cell	run 132	proteomic profiling by mass spectrometry	UM_A_2010_0012_a3-GRANTA519.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0012_a3-GRANTA519.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Granta 519	no compound
Sample 45	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	Lymphocyte	L1236	no compound	glycosylation	3	cell	run 133	proteomic profiling by mass spectrometry	UM_A_2010_0013_a1-L1236.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0013_a1-L1236.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L1236	no compound
Sample 45	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	Lymphocyte	L1236	no compound	glycosylation	3	cell	run 134	proteomic profiling by mass spectrometry	UM_A_2010_0013_a2-L1236.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0013_a2-L1236.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L1236	no compound
Sample 45	Homo sapiens	lymph node	not available	not available	Classical Hodgkin lymphoma	not available	Lymphocyte	L1236	no compound	glycosylation	3	cell	run 135	proteomic profiling by mass spectrometry	UM_A_2010_0013_a3-L1236.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2010_0013_a3-L1236.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	L1236	no compound
Sample 46	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-18	no compound	glycosylation	1	cell	run 136	proteomic profiling by mass spectrometry	UM_A_2011_0276_a1-FL18.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0276_a1-FL18.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-18	no compound
Sample 46	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-18	no compound	glycosylation	1	cell	run 137	proteomic profiling by mass spectrometry	UM_A_2011_0276_a2-FL18.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0276_a2-FL18.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-18	no compound
Sample 46	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-18	no compound	glycosylation	1	cell	run 138	proteomic profiling by mass spectrometry	UM_A_2011_0276_a3-FL18.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0276_a3-FL18.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-18	no compound
Sample 47	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-318	no compound	glycosylation	1	cell	run 139	proteomic profiling by mass spectrometry	UM_A_2011_0277_a1-FL318.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0277_a1-FL318.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-318	no compound
Sample 47	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-318	no compound	glycosylation	1	cell	run 140	proteomic profiling by mass spectrometry	UM_A_2011_0277_a2-FL318.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0277_a2-FL318.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-318	no compound
Sample 47	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-318	no compound	glycosylation	1	cell	run 141	proteomic profiling by mass spectrometry	UM_A_2011_0277_a3-FL318.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0277_a3-FL318.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-318	no compound
Sample 48	Homo sapiens	lymph node	not available	not available	Burkitt lymphoma	not available	B lymphocyte	BJA-B	no compound	glycosylation	1	cell	run 142	proteomic profiling by mass spectrometry	UM_A_2011_0316_a1-BJAB.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0316_a1-BJAB.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	BJA-B	no compound
Sample 48	Homo sapiens	lymph node	not available	not available	Burkitt lymphoma	not available	B lymphocyte	BJA-B	no compound	glycosylation	1	cell	run 143	proteomic profiling by mass spectrometry	UM_A_2011_0316_a2-BJAB.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0316_a2-BJAB.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	BJA-B	no compound
Sample 48	Homo sapiens	lymph node	not available	not available	Burkitt lymphoma	not available	B lymphocyte	BJA-B	no compound	glycosylation	1	cell	run 144	proteomic profiling by mass spectrometry	UM_A_2011_0316_a3-BJAB.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0316_a3-BJAB.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	BJA-B	no compound
Sample 49	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-318	no compound	glycosylation	2	cell	run 145	proteomic profiling by mass spectrometry	UM_A_2011_0318_a1-FL318.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0318_a1-FL318.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-318	no compound
Sample 49	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-318	no compound	glycosylation	2	cell	run 146	proteomic profiling by mass spectrometry	UM_A_2011_0318_a2-FL318.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0318_a2-FL318.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-318	no compound
Sample 49	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-318	no compound	glycosylation	2	cell	run 147	proteomic profiling by mass spectrometry	UM_A_2011_0318_a3-FL318.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0318_a3-FL318.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-318	no compound
Sample 50	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-18	no compound	glycosylation	2	cell	run 148	proteomic profiling by mass spectrometry	UM_A_2011_0353_a1-FL18.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0353_a1-FL18.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-18	no compound
Sample 50	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-18	no compound	glycosylation	2	cell	run 149	proteomic profiling by mass spectrometry	UM_A_2011_0353_a2-FL18.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0353_a2-FL18.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-18	no compound
Sample 50	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-18	no compound	glycosylation	2	cell	run 150	proteomic profiling by mass spectrometry	UM_A_2011_0353_a3-FL18.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0353_a3-FL18.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-18	no compound
Sample 51	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-518	no compound	glycosylation	1	cell	run 151	proteomic profiling by mass spectrometry	UM_A_2011_0354_a1-FL518.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0354_a1-FL518.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-518	no compound
Sample 51	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-518	no compound	glycosylation	1	cell	run 152	proteomic profiling by mass spectrometry	UM_A_2011_0354_a2-FL518.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0354_a2-FL518.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-518	no compound
Sample 51	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-518	no compound	glycosylation	1	cell	run 153	proteomic profiling by mass spectrometry	UM_A_2011_0354_a3-FL518.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0354_a3-FL518.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-518	no compound
Sample 52	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-18	no compound	glycosylation	3	cell	run 154	proteomic profiling by mass spectrometry	UM_A_2011_0509_a1-FL18.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0509_a1-FL18.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-18	no compound
Sample 52	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-18	no compound	glycosylation	3	cell	run 155	proteomic profiling by mass spectrometry	UM_A_2011_0509_a2-FL18.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0509_a2-FL18.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-18	no compound
Sample 52	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-18	no compound	glycosylation	3	cell	run 156	proteomic profiling by mass spectrometry	UM_A_2011_0509_a3-FL18.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0509_a3-FL18.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-18	no compound
Sample 53	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-318	no compound	glycosylation	3	cell	run 157	proteomic profiling by mass spectrometry	UM_A_2011_0510_a1-FL318.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0510_a1-FL318.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-318	no compound
Sample 53	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-318	no compound	glycosylation	3	cell	run 158	proteomic profiling by mass spectrometry	UM_A_2011_0510_a2-FL318.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0510_a2-FL318.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-318	no compound
Sample 53	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-318	no compound	glycosylation	3	cell	run 159	proteomic profiling by mass spectrometry	UM_A_2011_0510_a3-FL318.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0510_a3-FL318.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-318	no compound
Sample 54	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-518	no compound	glycosylation	2	cell	run 160	proteomic profiling by mass spectrometry	UM_A_2011_0511_a1-FL518.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0511_a1-FL518.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-518	no compound
Sample 54	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-518	no compound	glycosylation	2	cell	run 161	proteomic profiling by mass spectrometry	UM_A_2011_0511_a2-FL518.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0511_a2-FL518.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-518	no compound
Sample 54	Homo sapiens	lymph node	not available	not available	Transformed follicular lymphoma	not available	B lymphocyte	FL-518	no compound	glycosylation	2	cell	run 162	proteomic profiling by mass spectrometry	UM_A_2011_0511_a3-FL518.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0511_a3-FL518.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-518	no compound
Sample 55	Homo sapiens	lymph node	not available	not available	Burkitt lymphoma	not available	B lymphocyte	BJA-B	no compound	glycosylation	2	cell	run 163	proteomic profiling by mass spectrometry	UM_A_2011_0513_a1-BJAB.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0513_a1-BJAB.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	BJA-B	no compound
Sample 55	Homo sapiens	lymph node	not available	not available	Burkitt lymphoma	not available	B lymphocyte	BJA-B	no compound	glycosylation	2	cell	run 164	proteomic profiling by mass spectrometry	UM_A_2011_0513_a2-BJAB.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0513_a2-BJAB.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	BJA-B	no compound
Sample 55	Homo sapiens	lymph node	not available	not available	Burkitt lymphoma	not available	B lymphocyte	BJA-B	no compound	glycosylation	2	cell	run 165	proteomic profiling by mass spectrometry	UM_A_2011_0513_a3-BJAB.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0513_a3-BJAB.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	BJA-B	no compound
Sample 56	Homo sapiens	lymph node	not available	not available	Burkitt lymphoma	not available	B lymphocyte	FL-518	no compound	glycosylation	3	cell	run 166	proteomic profiling by mass spectrometry	UM_A_2011_0714_a1-FL518.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0714_a1-FL518.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-518	no compound
Sample 56	Homo sapiens	lymph node	not available	not available	Burkitt lymphoma	not available	B lymphocyte	FL-518	no compound	glycosylation	3	cell	run 167	proteomic profiling by mass spectrometry	UM_A_2011_0714_a2-FL518.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0714_a2-FL518.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-518	no compound
Sample 56	Homo sapiens	lymph node	not available	not available	Burkitt lymphoma	not available	B lymphocyte	FL-518	no compound	glycosylation	3	cell	run 168	proteomic profiling by mass spectrometry	UM_A_2011_0714_a3-FL518.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0714_a3-FL518.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	FL-518	no compound
Sample 57	Homo sapiens	lymph node	44Y	male	Transformed follicular lymphoma	not available	B lymphocyte	OCI-Ly1	no compound	glycosylation	1	cell	run 169	proteomic profiling by mass spectrometry	UM_A_2011_0912_a1-OCILY1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0912_a1-OCILY1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly1	no compound
Sample 57	Homo sapiens	lymph node	44Y	male	Transformed follicular lymphoma	not available	B lymphocyte	OCI-Ly1	no compound	glycosylation	1	cell	run 170	proteomic profiling by mass spectrometry	UM_A_2011_0912_a2-OCILY1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0912_a2-OCILY1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly1	no compound
Sample 57	Homo sapiens	lymph node	44Y	male	Transformed follicular lymphoma	not available	B lymphocyte	OCI-Ly1	no compound	glycosylation	1	cell	run 171	proteomic profiling by mass spectrometry	UM_A_2011_0912_a3-OCILY1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0912_a3-OCILY1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly1	no compound
Sample 58	Homo sapiens	lymph node	57Y	male	Mantle cell lymphoma	not available	lymphoblast	Rec-1	no compound	glycosylation	1	cell	run 172	proteomic profiling by mass spectrometry	UM_A_2011_0913_a1-REC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0913_a1-REC1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Rec-1	no compound
Sample 58	Homo sapiens	lymph node	57Y	male	Mantle cell lymphoma	not available	lymphoblast	Rec-1	no compound	glycosylation	1	cell	run 173	proteomic profiling by mass spectrometry	UM_A_2011_0913_a2-REC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0913_a2-REC1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Rec-1	no compound
Sample 58	Homo sapiens	lymph node	57Y	male	Mantle cell lymphoma	not available	lymphoblast	Rec-1	no compound	glycosylation	1	cell	run 174	proteomic profiling by mass spectrometry	UM_A_2011_0913_a3-REC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0913_a3-REC1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Rec-1	no compound
Sample 59	Homo sapiens	lymph node	44Y	male	Transformed follicular lymphoma	not available	B lymphocyte	OCI-Ly1	no compound	glycosylation	2	cell	run 175	proteomic profiling by mass spectrometry	UM_A_2011_0932_a1-OCILY1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0932_a1-OCILY1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly1	no compound
Sample 59	Homo sapiens	lymph node	44Y	male	Transformed follicular lymphoma	not available	B lymphocyte	OCI-Ly1	no compound	glycosylation	2	cell	run 176	proteomic profiling by mass spectrometry	UM_A_2011_0932_a2-OCILY1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0932_a2-OCILY1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly1	no compound
Sample 59	Homo sapiens	lymph node	44Y	male	Transformed follicular lymphoma	not available	B lymphocyte	OCI-Ly1	no compound	glycosylation	2	cell	run 177	proteomic profiling by mass spectrometry	UM_A_2011_0932_a3-OCILY1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0932_a3-OCILY1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly1	no compound
Sample 60	Homo sapiens	lymph node	57Y	male	Mantle cell lymphoma	not available	lymphoblast	Rec-1	no compound	glycosylation	2	cell	run 178	proteomic profiling by mass spectrometry	UM_A_2011_0933_a1-REC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0933_a1-REC1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Rec-1	no compound
Sample 60	Homo sapiens	lymph node	57Y	male	Mantle cell lymphoma	not available	lymphoblast	Rec-1	no compound	glycosylation	2	cell	run 179	proteomic profiling by mass spectrometry	UM_A_2011_0933_a2-REC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0933_a2-REC1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Rec-1	no compound
Sample 60	Homo sapiens	lymph node	57Y	male	Mantle cell lymphoma	not available	lymphoblast	Rec-1	no compound	glycosylation	2	cell	run 180	proteomic profiling by mass spectrometry	UM_A_2011_0933_a3-REC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0933_a3-REC1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Rec-1	no compound
Sample 61	Homo sapiens	lymph node	57Y	male	Mantle cell lymphoma	not available	lymphoblast	Rec-1	no compound	glycosylation	3	cell	run 181	proteomic profiling by mass spectrometry	UM_A_2011_0935_a1-REC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0935_a1-REC1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Rec-1	no compound
Sample 61	Homo sapiens	lymph node	57Y	male	Mantle cell lymphoma	not available	lymphoblast	Rec-1	no compound	glycosylation	3	cell	run 182	proteomic profiling by mass spectrometry	UM_A_2011_0935_a2-REC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0935_a2-REC1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Rec-1	no compound
Sample 61	Homo sapiens	lymph node	57Y	male	Mantle cell lymphoma	not available	lymphoblast	Rec-1	no compound	glycosylation	3	cell	run 183	proteomic profiling by mass spectrometry	UM_A_2011_0935_a3-REC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0935_a3-REC1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Rec-1	no compound
Sample 62	Homo sapiens	lymph node	44Y	male	Transformed follicular lymphoma	not available	B lymphocyte	OCI-Ly1	no compound	glycosylation	3	cell	run 184	proteomic profiling by mass spectrometry	UM_A_2011_0936_a1-OCILY1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0936_a1-OCILY1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly1	no compound
Sample 62	Homo sapiens	lymph node	44Y	male	Transformed follicular lymphoma	not available	B lymphocyte	OCI-Ly1	no compound	glycosylation	3	cell	run 185	proteomic profiling by mass spectrometry	UM_A_2011_0936_a2-OCILY1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0936_a2-OCILY1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly1	no compound
Sample 62	Homo sapiens	lymph node	44Y	male	Transformed follicular lymphoma	not available	B lymphocyte	OCI-Ly1	no compound	glycosylation	3	cell	run 186	proteomic profiling by mass spectrometry	UM_A_2011_0936_a3-OCILY1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_0936_a3-OCILY1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	OCI-Ly1	no compound
Sample 63	Homo sapiens	lymph node	not available	not available	Burkitt lymphoma	not available	B lymphocyte	BJA-B	no compound	glycosylation	3	cell	run 187	proteomic profiling by mass spectrometry	UM_A_2011_1051_a1-BJAB.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_1051_a1-BJAB.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	BJA-B	no compound
Sample 63	Homo sapiens	lymph node	not available	not available	Burkitt lymphoma	not available	B lymphocyte	BJA-B	no compound	glycosylation	3	cell	run 188	proteomic profiling by mass spectrometry	UM_A_2011_1051_a2-BJAB.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_1051_a2-BJAB.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	BJA-B	no compound
Sample 63	Homo sapiens	lymph node	not available	not available	Burkitt lymphoma	not available	B lymphocyte	BJA-B	no compound	glycosylation	3	cell	run 189	proteomic profiling by mass spectrometry	UM_A_2011_1051_a3-BJAB.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_1051_a3-BJAB.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	BJA-B	no compound
Sample 64	Homo sapiens	peripheral blood	61Y	male	cutaneous T cell lymphoma	Caucasian	T lymphocyte	HH	no compound	glycosylation	1	cell	run 190	proteomic profiling by mass spectrometry	UM_A_2011_1311_a1-HH.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_1311_a1-HH.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	HH	no compound
Sample 64	Homo sapiens	peripheral blood	61Y	male	cutaneous T cell lymphoma	Caucasian	T lymphocyte	HH	no compound	glycosylation	1	cell	run 191	proteomic profiling by mass spectrometry	UM_A_2011_1311_a2-HH.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_1311_a2-HH.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	HH	no compound
Sample 64	Homo sapiens	peripheral blood	61Y	male	cutaneous T cell lymphoma	Caucasian	T lymphocyte	HH	no compound	glycosylation	1	cell	run 192	proteomic profiling by mass spectrometry	UM_A_2011_1311_a3-HH.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_1311_a3-HH.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	HH	no compound
Sample 65	Homo sapiens	peripheral blood	61Y	male	cutaneous T cell lymphoma	Caucasian	T lymphocyte	HH	no compound	glycosylation	2	cell	run 193	proteomic profiling by mass spectrometry	UM_A_2011_1312_a1-HH.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_1312_a1-HH.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	HH	no compound
Sample 65	Homo sapiens	peripheral blood	61Y	male	cutaneous T cell lymphoma	Caucasian	T lymphocyte	HH	no compound	glycosylation	2	cell	run 194	proteomic profiling by mass spectrometry	UM_A_2011_1312_a2-HH.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_1312_a2-HH.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	HH	no compound
Sample 65	Homo sapiens	peripheral blood	61Y	male	cutaneous T cell lymphoma	Caucasian	T lymphocyte	HH	no compound	glycosylation	2	cell	run 195	proteomic profiling by mass spectrometry	UM_A_2011_1312_a3-HH.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2011_1312_a3-HH.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	HH	no compound
Sample 66	Homo sapiens	peripheral blood	61Y	male	cutaneous T cell lymphoma	Caucasian	T lymphocyte	HH	no compound	glycosylation	3	cell	run 196	proteomic profiling by mass spectrometry	UM_A_2012_0175_a1-HH.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0175_a1-HH.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	HH	no compound
Sample 66	Homo sapiens	peripheral blood	61Y	male	cutaneous T cell lymphoma	Caucasian	T lymphocyte	HH	no compound	glycosylation	3	cell	run 197	proteomic profiling by mass spectrometry	UM_A_2012_0175_a2-HH.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0175_a2-HH.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	HH	no compound
Sample 66	Homo sapiens	peripheral blood	61Y	male	cutaneous T cell lymphoma	Caucasian	T lymphocyte	HH	no compound	glycosylation	3	cell	run 198	proteomic profiling by mass spectrometry	UM_A_2012_0175_a3-HH.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0175_a3-HH.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	HH	no compound
Sample 67	Homo sapiens	T lymphocyte	53Y	male	Sezary Syndrome	Caucasian	cutaneous T lymphocyte	Hut-78	no compound	glycosylation	1	cell	run 199	proteomic profiling by mass spectrometry	UM_A_2012_0218_a1-HUT78.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0218_a1-HUT78.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Hut-78	no compound
Sample 67	Homo sapiens	T lymphocyte	53Y	male	Sezary Syndrome	Caucasian	cutaneous T lymphocyte	Hut-78	no compound	glycosylation	1	cell	run 200	proteomic profiling by mass spectrometry	UM_A_2012_0218_a2-HUT78.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0218_a2-HUT78.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Hut-78	no compound
Sample 67	Homo sapiens	T lymphocyte	53Y	male	Sezary Syndrome	Caucasian	cutaneous T lymphocyte	Hut-78	no compound	glycosylation	1	cell	run 201	proteomic profiling by mass spectrometry	UM_A_2012_0218_a3-HUT78.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0218_a3-HUT78.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Hut-78	no compound
Sample 68	Homo sapiens	T lymphocyte	53Y	male	Sezary Syndrome	Caucasian	cutaneous T lymphocyte	Hut-78	no compound	glycosylation	2	cell	run 202	proteomic profiling by mass spectrometry	UM_A_2012_0471_a1-HUT78.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0471_a1-HUT78.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Hut-78	no compound
Sample 68	Homo sapiens	T lymphocyte	53Y	male	Sezary Syndrome	Caucasian	cutaneous T lymphocyte	Hut-78	no compound	glycosylation	2	cell	run 203	proteomic profiling by mass spectrometry	UM_A_2012_0471_a2-HUT78.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0471_a2-HUT78.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Hut-78	no compound
Sample 68	Homo sapiens	T lymphocyte	53Y	male	Sezary Syndrome	Caucasian	cutaneous T lymphocyte	Hut-78	no compound	glycosylation	2	cell	run 204	proteomic profiling by mass spectrometry	UM_A_2012_0471_a3-HUT78.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0471_a3-HUT78.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Hut-78	no compound
Sample 69	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	no compound	glycosylation	1	cell	run 205	proteomic profiling by mass spectrometry	UM_A_2012_0581_a1-KARPAS299.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0581_a1-KARPAS299.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	no compound
Sample 69	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	no compound	glycosylation	1	cell	run 206	proteomic profiling by mass spectrometry	UM_A_2012_0581_a2-KARPAS299.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0581_a2-KARPAS299.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	no compound
Sample 69	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	no compound	glycosylation	1	cell	run 207	proteomic profiling by mass spectrometry	UM_A_2012_0581_a3-KARPAS299.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0581_a3-KARPAS299.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	no compound
Sample 70	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	no compound	glycosylation	2	cell	run 208	proteomic profiling by mass spectrometry	UM_A_2012_0582_a1-KARPAS299.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0582_a1-KARPAS299.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	no compound
Sample 70	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	no compound	glycosylation	2	cell	run 209	proteomic profiling by mass spectrometry	UM_A_2012_0582_a2-KARPAS299.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0582_a2-KARPAS299.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	no compound
Sample 70	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	no compound	glycosylation	2	cell	run 210	proteomic profiling by mass spectrometry	UM_A_2012_0582_a3-KARPAS299.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0582_a3-KARPAS299.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	no compound
Sample 71	Homo sapiens	lymph node	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SR-786	no compound	glycosylation	1	cell	run 211	proteomic profiling by mass spectrometry	UM_A_2012_0675_a1-SR786.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0675_a1-SR786.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SR-786	no compound
Sample 71	Homo sapiens	lymph node	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SR-786	no compound	glycosylation	1	cell	run 212	proteomic profiling by mass spectrometry	UM_A_2012_0675_a2-SR786.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0675_a2-SR786.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SR-786	no compound
Sample 71	Homo sapiens	lymph node	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SR-786	no compound	glycosylation	1	cell	run 213	proteomic profiling by mass spectrometry	UM_A_2012_0675_a3-SR786.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0675_a3-SR786.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SR-786	no compound
Sample 72	Homo sapiens	lymph node	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SR-786	no compound	glycosylation	2	cell	run 214	proteomic profiling by mass spectrometry	UM_A_2012_0677_a1-SR786.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0677_a1-SR786.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SR-786	no compound
Sample 72	Homo sapiens	lymph node	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SR-786	no compound	glycosylation	2	cell	run 215	proteomic profiling by mass spectrometry	UM_A_2012_0677_a2-SR786.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0677_a2-SR786.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SR-786	no compound
Sample 72	Homo sapiens	lymph node	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SR-786	no compound	glycosylation	2	cell	run 216	proteomic profiling by mass spectrometry	UM_A_2012_0677_a3-SR786.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0677_a3-SR786.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SR-786	no compound
Sample 73	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	no compound	glycosylation	3	cell	run 217	proteomic profiling by mass spectrometry	UM_A_2012_0715_a1-KARPAS299.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0715_a1-KARPAS299.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	no compound
Sample 73	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	no compound	glycosylation	3	cell	run 218	proteomic profiling by mass spectrometry	UM_A_2012_0715_a2-KARPAS299.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0715_a2-KARPAS299.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	no compound
Sample 73	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	no compound	glycosylation	3	cell	run 219	proteomic profiling by mass spectrometry	UM_A_2012_0715_a3-KARPAS299.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0715_a3-KARPAS299.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	no compound
Sample 74	Homo sapiens	Lymphoma	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SUP-M2	no compound	glycosylation	1	cell	run 220	proteomic profiling by mass spectrometry	UM_A_2012_0738_a1-SUPM2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0738_a1-SUPM2.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUP-M2	no compound
Sample 74	Homo sapiens	Lymphoma	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SUP-M2	no compound	glycosylation	1	cell	run 221	proteomic profiling by mass spectrometry	UM_A_2012_0738_a2-SUPM2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0738_a2-SUPM2.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUP-M2	no compound
Sample 74	Homo sapiens	Lymphoma	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SUP-M2	no compound	glycosylation	1	cell	run 222	proteomic profiling by mass spectrometry	UM_A_2012_0738_a3-SUPM2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0738_a3-SUPM2.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUP-M2	no compound
Sample 75	Homo sapiens	Lymphoma	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SUP-M2	no compound	glycosylation	2	cell	run 223	proteomic profiling by mass spectrometry	UM_A_2012_0739_a1-SUPM2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0739_a1-SUPM2.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUP-M2	no compound
Sample 75	Homo sapiens	Lymphoma	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SUP-M2	no compound	glycosylation	2	cell	run 224	proteomic profiling by mass spectrometry	UM_A_2012_0739_a2-SUPM2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0739_a2-SUPM2.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUP-M2	no compound
Sample 75	Homo sapiens	Lymphoma	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SUP-M2	no compound	glycosylation	2	cell	run 225	proteomic profiling by mass spectrometry	UM_A_2012_0739_a3-SUPM2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0739_a3-SUPM2.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUP-M2	no compound
Sample 76	Homo sapiens	Lymphoma	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SUP-M2	no compound	glycosylation	3	cell	run 226	proteomic profiling by mass spectrometry	UM_A_2012_0740_a1-SUPM2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0740_a1-SUPM2.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUP-M2	no compound
Sample 76	Homo sapiens	Lymphoma	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SUP-M2	no compound	glycosylation	3	cell	run 227	proteomic profiling by mass spectrometry	UM_A_2012_0740_a2-SUPM2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0740_a2-SUPM2.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUP-M2	no compound
Sample 76	Homo sapiens	Lymphoma	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SUP-M2	no compound	glycosylation	3	cell	run 228	proteomic profiling by mass spectrometry	UM_A_2012_0740_a3-SUPM2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0740_a3-SUPM2.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUP-M2	no compound
Sample 77	Homo sapiens	lymphoblastic	15Y	male	Aggressive NK-cell leukemia	not available	lymphoblastic	YT	no compound	glycosylation	1	cell	run 229	proteomic profiling by mass spectrometry	UM_A_2012_0770_a1-YT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0770_a1-YT.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	YT	no compound
Sample 77	Homo sapiens	lymphoblastic	15Y	male	Aggressive NK-cell leukemia	not available	lymphoblastic	YT	no compound	glycosylation	1	cell	run 230	proteomic profiling by mass spectrometry	UM_A_2012_0770_a2-YT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0770_a2-YT.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	YT	no compound
Sample 77	Homo sapiens	lymphoblastic	15Y	male	Aggressive NK-cell leukemia	not available	lymphoblastic	YT	no compound	glycosylation	1	cell	run 231	proteomic profiling by mass spectrometry	UM_A_2012_0770_a3-YT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0770_a3-YT.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	YT	no compound
Sample 78	Homo sapiens	lymphoblastic	15Y	male	Aggressive NK-cell leukemia	not available	lymphoblastic	YT	no compound	glycosylation	2	cell	run 232	proteomic profiling by mass spectrometry	UM_A_2012_0771_a1-YT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0771_a1-YT.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	YT	no compound
Sample 78	Homo sapiens	lymphoblastic	15Y	male	Aggressive NK-cell leukemia	not available	lymphoblastic	YT	no compound	glycosylation	2	cell	run 233	proteomic profiling by mass spectrometry	UM_A_2012_0771_a2-YT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0771_a2-YT.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	YT	no compound
Sample 78	Homo sapiens	lymphoblastic	15Y	male	Aggressive NK-cell leukemia	not available	lymphoblastic	YT	no compound	glycosylation	2	cell	run 234	proteomic profiling by mass spectrometry	UM_A_2012_0771_a3-YT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0771_a3-YT.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	YT	no compound
Sample 79	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-1	no compound	glycosylation	1	cell	run 235	proteomic profiling by mass spectrometry	UM_A_2012_0772_a1-MAC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0772_a1-MAC1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-1	no compound
Sample 79	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-1	no compound	glycosylation	1	cell	run 236	proteomic profiling by mass spectrometry	UM_A_2012_0772_a2-MAC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0772_a2-MAC1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-1	no compound
Sample 79	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-1	no compound	glycosylation	1	cell	run 237	proteomic profiling by mass spectrometry	UM_A_2012_0772_a3-MAC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0772_a3-MAC1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-1	no compound
Sample 80	Homo sapiens	lymph node	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SR-786	no compound	glycosylation	3	cell	run 238	proteomic profiling by mass spectrometry	UM_A_2012_0816_a1-SR786.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0816_a1-SR786.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SR-786	no compound
Sample 80	Homo sapiens	lymph node	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SR-786	no compound	glycosylation	3	cell	run 239	proteomic profiling by mass spectrometry	UM_A_2012_0816_a2-SR786.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0816_a2-SR786.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SR-786	no compound
Sample 80	Homo sapiens	lymph node	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	SR-786	no compound	glycosylation	3	cell	run 240	proteomic profiling by mass spectrometry	UM_A_2012_0816_a3-SR786.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0816_a3-SR786.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SR-786	no compound
Sample 81	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-1	no compound	glycosylation	2	cell	run 241	proteomic profiling by mass spectrometry	UM_A_2012_0818_a1-MAC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0818_a1-MAC1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-1	no compound
Sample 81	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-1	no compound	glycosylation	2	cell	run 242	proteomic profiling by mass spectrometry	UM_A_2012_0818_a2-MAC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0818_a2-MAC1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-1	no compound
Sample 81	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-1	no compound	glycosylation	2	cell	run 243	proteomic profiling by mass spectrometry	UM_A_2012_0818_a3-MAC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0818_a3-MAC1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-1	no compound
Sample 82	Homo sapiens	lymphoblastic	not available	male	acute T cell leukemia	not available	T lymphocyte	Jurkat	no compound	glycosylation	1	cell	run 244	proteomic profiling by mass spectrometry	UM_A_2012_0863_a1-JURKAT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0863_a1-JURKAT.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Jurkat	no compound
Sample 82	Homo sapiens	lymphoblastic	not available	male	acute T cell leukemia	not available	T lymphocyte	Jurkat	no compound	glycosylation	1	cell	run 245	proteomic profiling by mass spectrometry	UM_A_2012_0863_a2-JURKAT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0863_a2-JURKAT.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Jurkat	no compound
Sample 82	Homo sapiens	lymphoblastic	not available	male	acute T cell leukemia	not available	T lymphocyte	Jurkat	no compound	glycosylation	1	cell	run 246	proteomic profiling by mass spectrometry	UM_A_2012_0863_a3-JURKAT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0863_a3-JURKAT.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Jurkat	no compound
Sample 83	Homo sapiens	lymphoblastic	not available	male	acute T cell leukemia	not available	T lymphocyte	Jurkat	no compound	glycosylation	2	cell	run 247	proteomic profiling by mass spectrometry	UM_A_2012_0864_a1-JURKAT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0864_a1-JURKAT.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Jurkat	no compound
Sample 83	Homo sapiens	lymphoblastic	not available	male	acute T cell leukemia	not available	T lymphocyte	Jurkat	no compound	glycosylation	2	cell	run 248	proteomic profiling by mass spectrometry	UM_A_2012_0864_a2-JURKAT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0864_a2-JURKAT.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Jurkat	no compound
Sample 83	Homo sapiens	lymphoblastic	not available	male	acute T cell leukemia	not available	T lymphocyte	Jurkat	no compound	glycosylation	2	cell	run 249	proteomic profiling by mass spectrometry	UM_A_2012_0864_a3-JURKAT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0864_a3-JURKAT.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Jurkat	no compound
Sample 84	Homo sapiens	lymphoblastic	not available	male	acute T cell leukemia	not available	T lymphocyte	Jurkat	no compound	glycosylation	3	cell	run 250	proteomic profiling by mass spectrometry	UM_A_2012_0866_a1-JURKAT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0866_a1-JURKAT.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Jurkat	no compound
Sample 84	Homo sapiens	lymphoblastic	not available	male	acute T cell leukemia	not available	T lymphocyte	Jurkat	no compound	glycosylation	3	cell	run 251	proteomic profiling by mass spectrometry	UM_A_2012_0866_a2-JURKAT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0866_a2-JURKAT.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Jurkat	no compound
Sample 84	Homo sapiens	lymphoblastic	not available	male	acute T cell leukemia	not available	T lymphocyte	Jurkat	no compound	glycosylation	3	cell	run 252	proteomic profiling by mass spectrometry	UM_A_2012_0866_a3-JURKAT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0866_a3-JURKAT.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Jurkat	no compound
Sample 85	Homo sapiens	peripheral blood	75Y	female	Mantle cell lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 253	proteomic profiling by mass spectrometry	UM_A_2012_0916_a1-PATEINT_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0916_a1-PATEINT_3.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 85	Homo sapiens	peripheral blood	75Y	female	Mantle cell lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 254	proteomic profiling by mass spectrometry	UM_A_2012_0916_a2-PATEINT_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0916_a2-PATEINT_3.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 85	Homo sapiens	peripheral blood	75Y	female	Mantle cell lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 255	proteomic profiling by mass spectrometry	UM_A_2012_0916_a3-PATEINT_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0916_a3-PATEINT_3.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 86	Homo sapiens	peripheral blood	79Y	female	follicular lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 256	proteomic profiling by mass spectrometry	UM_A_2012_0917_a1-PATEINT_6.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0917_a1-PATEINT_6.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 86	Homo sapiens	peripheral blood	79Y	female	follicular lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 257	proteomic profiling by mass spectrometry	UM_A_2012_0917_a2-PATEINT_6.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0917_a2-PATEINT_6.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 86	Homo sapiens	peripheral blood	79Y	female	follicular lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 258	proteomic profiling by mass spectrometry	UM_A_2012_0917_a3-PATEINT_6.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0917_a3-PATEINT_6.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 87	Homo sapiens	peripheral blood	67Y	male	Mantle cell lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 259	proteomic profiling by mass spectrometry	UM_A_2012_0960_a1-PATEINT_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0960_a1-PATEINT_1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 87	Homo sapiens	peripheral blood	67Y	male	Mantle cell lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 260	proteomic profiling by mass spectrometry	UM_A_2012_0960_a2-PATEINT_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0960_a2-PATEINT_1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 87	Homo sapiens	peripheral blood	67Y	male	Mantle cell lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 261	proteomic profiling by mass spectrometry	UM_A_2012_0960_a3-PATEINT_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0960_a3-PATEINT_1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 88	Homo sapiens	peripheral blood	68Y	male	Mantle cell lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 262	proteomic profiling by mass spectrometry	UM_A_2012_0961_a1-PATEINT_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0961_a1-PATEINT_2.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 88	Homo sapiens	peripheral blood	68Y	male	Mantle cell lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 263	proteomic profiling by mass spectrometry	UM_A_2012_0961_a2-PATEINT_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0961_a2-PATEINT_2.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 88	Homo sapiens	peripheral blood	68Y	male	Mantle cell lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 264	proteomic profiling by mass spectrometry	UM_A_2012_0961_a3-PATEINT_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0961_a3-PATEINT_2.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 89	Homo sapiens	peripheral blood	55Y	female	Mantle cell lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 265	proteomic profiling by mass spectrometry	UM_A_2012_0962_a1-PATEINT_4.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0962_a1-PATEINT_4.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 89	Homo sapiens	peripheral blood	55Y	female	Mantle cell lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 266	proteomic profiling by mass spectrometry	UM_A_2012_0962_a2-PATEINT_4.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0962_a2-PATEINT_4.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 89	Homo sapiens	peripheral blood	55Y	female	Mantle cell lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 267	proteomic profiling by mass spectrometry	UM_A_2012_0962_a3-PATEINT_4.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0962_a3-PATEINT_4.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 90	Homo sapiens	peripheral blood	62Y	female	follicular lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 268	proteomic profiling by mass spectrometry	UM_A_2012_0963_a1-PATEINT_5.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0963_a1-PATEINT_5.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 90	Homo sapiens	peripheral blood	62Y	female	follicular lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 269	proteomic profiling by mass spectrometry	UM_A_2012_0963_a2-PATEINT_5.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0963_a2-PATEINT_5.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 90	Homo sapiens	peripheral blood	62Y	female	follicular lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 270	proteomic profiling by mass spectrometry	UM_A_2012_0963_a3-PATEINT_5.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0963_a3-PATEINT_5.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 91	Homo sapiens	peripheral blood	63Y	female	follicular lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 271	proteomic profiling by mass spectrometry	UM_A_2012_0964_a1-PATEINT_7.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0964_a1-PATEINT_7.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 91	Homo sapiens	peripheral blood	63Y	female	follicular lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 272	proteomic profiling by mass spectrometry	UM_A_2012_0964_a2-PATEINT_7.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0964_a2-PATEINT_7.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 91	Homo sapiens	peripheral blood	63Y	female	follicular lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 273	proteomic profiling by mass spectrometry	UM_A_2012_0964_a3-PATEINT_7.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0964_a3-PATEINT_7.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 92	Homo sapiens	peripheral blood	51Y	female	follicular lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 274	proteomic profiling by mass spectrometry	UM_A_2012_0965_a1-PATEINT_8.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0965_a1-PATEINT_8.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 92	Homo sapiens	peripheral blood	51Y	female	follicular lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 275	proteomic profiling by mass spectrometry	UM_A_2012_0965_a2-PATEINT_8.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0965_a2-PATEINT_8.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 92	Homo sapiens	peripheral blood	51Y	female	follicular lymphoma	not applicable	not applicable	not applicable	no compound	glycosylation	1	cell	run 276	proteomic profiling by mass spectrometry	UM_A_2012_0965_a3-PATEINT_8.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0965_a3-PATEINT_8.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	not applicable	no compound
Sample 93	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-2A	no compound	glycosylation	1	cell	run 277	proteomic profiling by mass spectrometry	UM_A_2012_0974_a1-MAC2A.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0974_a1-MAC2A.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-2A	no compound
Sample 93	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-2A	no compound	glycosylation	1	cell	run 278	proteomic profiling by mass spectrometry	UM_A_2012_0974_a2-MAC2A.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0974_a2-MAC2A.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-2A	no compound
Sample 93	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-2A	no compound	glycosylation	1	cell	run 279	proteomic profiling by mass spectrometry	UM_A_2012_0974_a3-MAC2A.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0974_a3-MAC2A.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-2A	no compound
Sample 94	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-2A	no compound	glycosylation	2	cell	run 280	proteomic profiling by mass spectrometry	UM_A_2012_0975_a1-MAC2A.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0975_a1-MAC2A.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-2A	no compound
Sample 94	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-2A	no compound	glycosylation	2	cell	run 281	proteomic profiling by mass spectrometry	UM_A_2012_0975_a2-MAC2A.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0975_a2-MAC2A.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-2A	no compound
Sample 94	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-2A	no compound	glycosylation	2	cell	run 282	proteomic profiling by mass spectrometry	UM_A_2012_0975_a3-MAC2A.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0975_a3-MAC2A.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-2A	no compound
Sample 95	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-2A	no compound	glycosylation	3	cell	run 283	proteomic profiling by mass spectrometry	UM_A_2012_0976_a1-MAC2A.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0976_a1-MAC2A.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-2A	no compound
Sample 95	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-2A	no compound	glycosylation	3	cell	run 284	proteomic profiling by mass spectrometry	UM_A_2012_0976_a2-MAC2A.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0976_a2-MAC2A.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-2A	no compound
Sample 95	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-2A	no compound	glycosylation	3	cell	run 285	proteomic profiling by mass spectrometry	UM_A_2012_0976_a3-MAC2A.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0976_a3-MAC2A.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-2A	no compound
Sample 96	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-1	no compound	glycosylation	3	cell	run 286	proteomic profiling by mass spectrometry	UM_A_2012_0977_a1-MAC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0977_a1-MAC1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-1	no compound
Sample 96	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-1	no compound	glycosylation	3	cell	run 287	proteomic profiling by mass spectrometry	UM_A_2012_0977_a2-MAC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0977_a2-MAC1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-1	no compound
Sample 96	Homo sapiens	lymphoblastic	not available	not available	Anaplastic large cell lymphoma	not available	T lymphocyte	Mac-1	no compound	glycosylation	3	cell	run 288	proteomic profiling by mass spectrometry	UM_A_2012_0977_a3-MAC1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0977_a3-MAC1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Mac-1	no compound
Sample 97	Homo sapiens	T lymphocyte	53Y	male	Sezary Syndrome	Caucasian	cutaneous T lymphocyte	Hut-78	no compound	glycosylation	3	cell	run 289	proteomic profiling by mass spectrometry	UM_A_2012_0978_a1-HUT78.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0978_a1-HUT78.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Hut-78	no compound
Sample 97	Homo sapiens	T lymphocyte	53Y	male	Sezary Syndrome	Caucasian	cutaneous T lymphocyte	Hut-78	no compound	glycosylation	3	cell	run 290	proteomic profiling by mass spectrometry	UM_A_2012_0978_a2-HUT78.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0978_a2-HUT78.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Hut-78	no compound
Sample 97	Homo sapiens	T lymphocyte	53Y	male	Sezary Syndrome	Caucasian	cutaneous T lymphocyte	Hut-78	no compound	glycosylation	3	cell	run 291	proteomic profiling by mass spectrometry	UM_A_2012_0978_a3-HUT78.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0978_a3-HUT78.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Hut-78	no compound
Sample 98	Homo sapiens	lymphoblastic	15Y	male	Aggressive NK-cell leukemia	not available	lymphoblastic	YT	no compound	glycosylation	3	cell	run 292	proteomic profiling by mass spectrometry	UM_A_2012_0979_a1-YT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0979_a1-YT.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	YT	no compound
Sample 98	Homo sapiens	lymphoblastic	15Y	male	Aggressive NK-cell leukemia	not available	lymphoblastic	YT	no compound	glycosylation	3	cell	run 293	proteomic profiling by mass spectrometry	UM_A_2012_0979_a2-YT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0979_a2-YT.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	YT	no compound
Sample 98	Homo sapiens	lymphoblastic	15Y	male	Aggressive NK-cell leukemia	not available	lymphoblastic	YT	no compound	glycosylation	3	cell	run 294	proteomic profiling by mass spectrometry	UM_A_2012_0979_a3-YT.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_0979_a3-YT.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	YT	no compound
Sample 99	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92MI	no compound	glycosylation	1	cell	run 295	proteomic profiling by mass spectrometry	UM_A_2012_1009_a1-NK92MI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1009_a1-NK92MI.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92MI	no compound
Sample 99	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92MI	no compound	glycosylation	1	cell	run 296	proteomic profiling by mass spectrometry	UM_A_2012_1009_a2-NK92MI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1009_a2-NK92MI.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92MI	no compound
Sample 99	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92MI	no compound	glycosylation	1	cell	run 297	proteomic profiling by mass spectrometry	UM_A_2012_1009_a3-NK92MI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1009_a3-NK92MI.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92MI	no compound
Sample 100	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92MI	no compound	glycosylation	2	cell	run 298	proteomic profiling by mass spectrometry	UM_A_2012_1010_a1-NK92MI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1010_a1-NK92MI.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92MI	no compound
Sample 100	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92MI	no compound	glycosylation	2	cell	run 299	proteomic profiling by mass spectrometry	UM_A_2012_1010_a2-NK92MI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1010_a2-NK92MI.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92MI	no compound
Sample 100	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92MI	no compound	glycosylation	2	cell	run 300	proteomic profiling by mass spectrometry	UM_A_2012_1010_a3-NK92MI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1010_a3-NK92MI.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92MI	no compound
Sample 101	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92MI	no compound	glycosylation	3	cell	run 301	proteomic profiling by mass spectrometry	UM_A_2012_1011_a1-NK92MI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1011_a1-NK92MI.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92MI	no compound
Sample 101	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92MI	no compound	glycosylation	3	cell	run 302	proteomic profiling by mass spectrometry	UM_A_2012_1011_a2-NK92MI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1011_a2-NK92MI.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92MI	no compound
Sample 101	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92MI	no compound	glycosylation	3	cell	run 303	proteomic profiling by mass spectrometry	UM_A_2012_1011_a3-NK92MI.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1011_a3-NK92MI.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92MI	no compound
Sample 102	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92	no compound	glycosylation	1	cell	run 304	proteomic profiling by mass spectrometry	UM_A_2012_1459_a1-NK92.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1459_a1-NK92.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92	no compound
Sample 102	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92	no compound	glycosylation	1	cell	run 305	proteomic profiling by mass spectrometry	UM_A_2012_1459_a2-NK92.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1459_a2-NK92.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92	no compound
Sample 102	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92	no compound	glycosylation	1	cell	run 306	proteomic profiling by mass spectrometry	UM_A_2012_1459_a3-NK92.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1459_a3-NK92.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92	no compound
Sample 103	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92	no compound	glycosylation	2	cell	run 307	proteomic profiling by mass spectrometry	UM_A_2012_1460_a1-NK92.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1460_a1-NK92.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92	no compound
Sample 103	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92	no compound	glycosylation	2	cell	run 308	proteomic profiling by mass spectrometry	UM_A_2012_1460_a2-NK92.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1460_a2-NK92.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92	no compound
Sample 103	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92	no compound	glycosylation	2	cell	run 309	proteomic profiling by mass spectrometry	UM_A_2012_1460_a3-NK92.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1460_a3-NK92.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92	no compound
Sample 104	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92	no compound	glycosylation	3	cell	run 310	proteomic profiling by mass spectrometry	UM_A_2012_1461_a1-NK92.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1461_a1-NK92.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92	no compound
Sample 104	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92	no compound	glycosylation	3	cell	run 311	proteomic profiling by mass spectrometry	UM_A_2012_1461_a2-NK92.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1461_a2-NK92.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92	no compound
Sample 104	Homo sapiens	peripheral blood	50Y	male	malignant non-Hodgkin's lymphoma	Caucasian	natural killer cell	NK-92	no compound	glycosylation	3	cell	run 312	proteomic profiling by mass spectrometry	UM_A_2012_1461_a3-NK92.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2012_1461_a3-NK92.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	NK-92	no compound
Sample 105	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	DMSO	glycosylation	1	cell	run 313	proteomic profiling by mass spectrometry	UM_A_2013_0202_a1-KARPAS299_DMSO_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0202_a1-KARPAS299_DMSO_1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	DMSO
Sample 105	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	DMSO	glycosylation	1	cell	run 314	proteomic profiling by mass spectrometry	UM_A_2013_0202_a2-KARPAS299_DMSO_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0202_a2-KARPAS299_DMSO_1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	DMSO
Sample 105	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	DMSO	glycosylation	1	cell	run 315	proteomic profiling by mass spectrometry	UM_A_2013_0202_a3-KARPAS299_DMSO_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0202_a3-KARPAS299_DMSO_1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	DMSO
Sample 106	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	ALK inhibitor	glycosylation	1	cell	run 316	proteomic profiling by mass spectrometry	UM_A_2013_0203_a1-KARPAS299_ALKI_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0203_a1-KARPAS299_ALKI_1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	ALK inhibitor
Sample 106	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	ALK inhibitor	glycosylation	1	cell	run 317	proteomic profiling by mass spectrometry	UM_A_2013_0203_a2-KARPAS299_ALKI_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0203_a2-KARPAS299_ALKI_1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	ALK inhibitor
Sample 106	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	ALK inhibitor	glycosylation	1	cell	run 318	proteomic profiling by mass spectrometry	UM_A_2013_0203_a3-KARPAS299_ALKI_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0203_a3-KARPAS299_ALKI_1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	ALK inhibitor
Sample 107	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	DMSO	glycosylation	2	cell	run 319	proteomic profiling by mass spectrometry	UM_A_2013_0204_a1-KARPAS299_DMSO_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0204_a1-KARPAS299_DMSO_2.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	DMSO
Sample 107	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	DMSO	glycosylation	2	cell	run 320	proteomic profiling by mass spectrometry	UM_A_2013_0204_a2-KARPAS299_DMSO_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0204_a2-KARPAS299_DMSO_2.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	DMSO
Sample 107	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	DMSO	glycosylation	2	cell	run 321	proteomic profiling by mass spectrometry	UM_A_2013_0204_a3-KARPAS299_DMSO_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0204_a3-KARPAS299_DMSO_2.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	DMSO
Sample 108	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	ALK inhibitor	glycosylation	2	cell	run 322	proteomic profiling by mass spectrometry	UM_A_2013_0205_a1-KARPAS299_ALKI_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0205_a1-KARPAS299_ALKI_2.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	ALK inhibitor
Sample 108	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	ALK inhibitor	glycosylation	2	cell	run 323	proteomic profiling by mass spectrometry	UM_A_2013_0205_a2-KARPAS299_ALKI_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0205_a2-KARPAS299_ALKI_2.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	ALK inhibitor
Sample 108	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	ALK inhibitor	glycosylation	2	cell	run 324	proteomic profiling by mass spectrometry	UM_A_2013_0205_a3-KARPAS299_ALKI_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0205_a3-KARPAS299_ALKI_2.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	ALK inhibitor
Sample 109	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	DMSO	glycosylation	1	cell	run 325	proteomic profiling by mass spectrometry	UM_A_2013_0206_a1-SUDHL1_DMSO_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0206_a1-SUDHL1_DMSO_1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	DMSO
Sample 109	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	DMSO	glycosylation	1	cell	run 326	proteomic profiling by mass spectrometry	UM_A_2013_0206_a2-SUDHL1_DMSO_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0206_a2-SUDHL1_DMSO_1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	DMSO
Sample 109	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	DMSO	glycosylation	1	cell	run 327	proteomic profiling by mass spectrometry	UM_A_2013_0206_a3-SUDHL1_DMSO_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0206_a3-SUDHL1_DMSO_1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	DMSO
Sample 110	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	ALK inhibitor	glycosylation	1	cell	run 328	proteomic profiling by mass spectrometry	UM_A_2013_0207_a1-SUDHL1_ALKI_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0207_a1-SUDHL1_ALKI_1.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	ALK inhibitor
Sample 110	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	ALK inhibitor	glycosylation	1	cell	run 329	proteomic profiling by mass spectrometry	UM_A_2013_0207_a2-SUDHL1_ALKI_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0207_a2-SUDHL1_ALKI_1.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	ALK inhibitor
Sample 110	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	ALK inhibitor	glycosylation	1	cell	run 330	proteomic profiling by mass spectrometry	UM_A_2013_0207_a3-SUDHL1_ALKI_1.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0207_a3-SUDHL1_ALKI_1.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	ALK inhibitor
Sample 111	Homo sapiens	peripheral blood	61Y	male	plasmacytoma	not available	B lymphocyte	RPMI 8226	no compound	glycosylation	1	cell	run 331	proteomic profiling by mass spectrometry	UM_A_2013_0230_a1-RPMI8226.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0230_a1-RPMI8226.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	RPMI 8226	no compound
Sample 111	Homo sapiens	peripheral blood	61Y	male	plasmacytoma	not available	B lymphocyte	RPMI 8226	no compound	glycosylation	1	cell	run 332	proteomic profiling by mass spectrometry	UM_A_2013_0230_a2-RPMI8226.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0230_a2-RPMI8226.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	RPMI 8226	no compound
Sample 111	Homo sapiens	peripheral blood	61Y	male	plasmacytoma	not available	B lymphocyte	RPMI 8226	no compound	glycosylation	1	cell	run 333	proteomic profiling by mass spectrometry	UM_A_2013_0230_a3-RPMI8226.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0230_a3-RPMI8226.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	RPMI 8226	no compound
Sample 112	Homo sapiens	peripheral blood	not available	female	Multiple Myeloma	not available	B lymphocyte	KMS-11	no compound	glycosylation	1	cell	run 334	proteomic profiling by mass spectrometry	UM_A_2013_0231_a1-KMS11.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0231_a1-KMS11.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-11	no compound
Sample 112	Homo sapiens	peripheral blood	not available	female	Multiple Myeloma	not available	B lymphocyte	KMS-11	no compound	glycosylation	1	cell	run 335	proteomic profiling by mass spectrometry	UM_A_2013_0231_a2-KMS11.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0231_a2-KMS11.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-11	no compound
Sample 112	Homo sapiens	peripheral blood	not available	female	Multiple Myeloma	not available	B lymphocyte	KMS-11	no compound	glycosylation	1	cell	run 336	proteomic profiling by mass spectrometry	UM_A_2013_0231_a3-KMS11.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0231_a3-KMS11.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-11	no compound
Sample 113	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	DMSO	glycosylation	3	cell	run 337	proteomic profiling by mass spectrometry	UM_A_2013_0232_a1-KARPAS299_DMSO_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0232_a1-KARPAS299_DMSO_3.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	DMSO
Sample 113	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	DMSO	glycosylation	3	cell	run 338	proteomic profiling by mass spectrometry	UM_A_2013_0232_a2-KARPAS299_DMSO_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0232_a2-KARPAS299_DMSO_3.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	DMSO
Sample 113	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	DMSO	glycosylation	3	cell	run 339	proteomic profiling by mass spectrometry	UM_A_2013_0232_a3-KARPAS299_DMSO_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0232_a3-KARPAS299_DMSO_3.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	DMSO
Sample 114	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	ALK inhibitor	glycosylation	3	cell	run 340	proteomic profiling by mass spectrometry	UM_A_2013_0233_a1-KARPAS299_ALKI_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0233_a1-KARPAS299_ALKI_3.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	ALK inhibitor
Sample 114	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	ALK inhibitor	glycosylation	3	cell	run 341	proteomic profiling by mass spectrometry	UM_A_2013_0233_a2-KARPAS299_ALKI_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0233_a2-KARPAS299_ALKI_3.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	ALK inhibitor
Sample 114	Homo sapiens	Lymphoma	not available	not available	"Anaplastic large cell lymphoma,"	not available	T lymphocyte	Karpas 299	ALK inhibitor	glycosylation	3	cell	run 342	proteomic profiling by mass spectrometry	UM_A_2013_0233_a3-KARPAS299_ALKI_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0233_a3-KARPAS299_ALKI_3.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	Karpas 299	ALK inhibitor
Sample 115	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	DMSO	glycosylation	2	cell	run 343	proteomic profiling by mass spectrometry	UM_A_2013_0234_a1-SUDHL1_DMSO_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0234_a1-SUDHL1_DMSO_2.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	DMSO
Sample 115	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	DMSO	glycosylation	2	cell	run 344	proteomic profiling by mass spectrometry	UM_A_2013_0234_a2-SUDHL1_DMSO_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0234_a2-SUDHL1_DMSO_2.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	DMSO
Sample 115	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	DMSO	glycosylation	2	cell	run 345	proteomic profiling by mass spectrometry	UM_A_2013_0234_a3-SUDHL1_DMSO_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0234_a3-SUDHL1_DMSO_2.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	DMSO
Sample 116	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	ALK inhibitor	glycosylation	2	cell	run 346	proteomic profiling by mass spectrometry	UM_A_2013_0235_a1-SUDHL1_ALKI_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0235_a1-SUDHL1_ALKI_2.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	ALK inhibitor
Sample 116	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	ALK inhibitor	glycosylation	2	cell	run 347	proteomic profiling by mass spectrometry	UM_A_2013_0235_a2-SUDHL1_ALKI_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0235_a2-SUDHL1_ALKI_2.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	ALK inhibitor
Sample 116	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	ALK inhibitor	glycosylation	2	cell	run 348	proteomic profiling by mass spectrometry	UM_A_2013_0235_a3-SUDHL1_ALKI_2.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0235_a3-SUDHL1_ALKI_2.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	ALK inhibitor
Sample 117	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	DMSO	glycosylation	3	cell	run 349	proteomic profiling by mass spectrometry	UM_A_2013_0236_a1-SUDHL1_DMSO_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0236_a1-SUDHL1_DMSO_3.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	DMSO
Sample 117	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	DMSO	glycosylation	3	cell	run 350	proteomic profiling by mass spectrometry	UM_A_2013_0236_a2-SUDHL1_DMSO_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0236_a2-SUDHL1_DMSO_3.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	DMSO
Sample 117	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	DMSO	glycosylation	3	cell	run 351	proteomic profiling by mass spectrometry	UM_A_2013_0236_a3-SUDHL1_DMSO_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0236_a3-SUDHL1_DMSO_3.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	DMSO
Sample 118	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	ALK inhibitor	glycosylation	3	cell	run 352	proteomic profiling by mass spectrometry	UM_A_2013_0237_a1-SUDHL1_ALKI_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0237_a1-SUDHL1_ALKI_3.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	ALK inhibitor
Sample 118	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	ALK inhibitor	glycosylation	3	cell	run 353	proteomic profiling by mass spectrometry	UM_A_2013_0237_a2-SUDHL1_ALKI_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0237_a2-SUDHL1_ALKI_3.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	ALK inhibitor
Sample 118	Homo sapiens	lymph node	10Y	male	diffuse histiocytic lymphoma	Caucasian	histiocytic	SUD-HL-1	ALK inhibitor	glycosylation	3	cell	run 354	proteomic profiling by mass spectrometry	UM_A_2013_0237_a3-SUDHL1_ALKI_3.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0237_a3-SUDHL1_ALKI_3.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	SUD-HL-1	ALK inhibitor
Sample 119	Homo sapiens	peripheral blood	not available	female	Multiple Myeloma	not available	B lymphocyte	KMS-11	no compound	glycosylation	2	cell	run 355	proteomic profiling by mass spectrometry	UM_A_2013_0246_a1-KMS11.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0246_a1-KMS11.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-11	no compound
Sample 119	Homo sapiens	peripheral blood	not available	female	Multiple Myeloma	not available	B lymphocyte	KMS-11	no compound	glycosylation	2	cell	run 356	proteomic profiling by mass spectrometry	UM_A_2013_0246_a2-KMS11.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0246_a2-KMS11.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-11	no compound
Sample 119	Homo sapiens	peripheral blood	not available	female	Multiple Myeloma	not available	B lymphocyte	KMS-11	no compound	glycosylation	2	cell	run 357	proteomic profiling by mass spectrometry	UM_A_2013_0246_a3-KMS11.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0246_a3-KMS11.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-11	no compound
Sample 120	Homo sapiens	peripheral blood	61Y	male	plasmacytoma	not available	B lymphocyte	RPMI 8226	no compound	glycosylation	2	cell	run 358	proteomic profiling by mass spectrometry	UM_A_2013_0247_a1-RPMI8226.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0247_a1-RPMI8226.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	RPMI 8226	no compound
Sample 120	Homo sapiens	peripheral blood	61Y	male	plasmacytoma	not available	B lymphocyte	RPMI 8226	no compound	glycosylation	2	cell	run 359	proteomic profiling by mass spectrometry	UM_A_2013_0247_a2-RPMI8226.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0247_a2-RPMI8226.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	RPMI 8226	no compound
Sample 120	Homo sapiens	peripheral blood	61Y	male	plasmacytoma	not available	B lymphocyte	RPMI 8226	no compound	glycosylation	2	cell	run 360	proteomic profiling by mass spectrometry	UM_A_2013_0247_a3-RPMI8226.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0247_a3-RPMI8226.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	RPMI 8226	no compound
Sample 121	Homo sapiens	peripheral blood	not available	female	Multiple Myeloma	not available	B lymphocyte	KMS-11	no compound	glycosylation	3	cell	run 361	proteomic profiling by mass spectrometry	UM_A_2013_0250_a1-KMS11.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0250_a1-KMS11.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-11	no compound
Sample 121	Homo sapiens	peripheral blood	not available	female	Multiple Myeloma	not available	B lymphocyte	KMS-11	no compound	glycosylation	3	cell	run 362	proteomic profiling by mass spectrometry	UM_A_2013_0250_a2-KMS11.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0250_a2-KMS11.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-11	no compound
Sample 121	Homo sapiens	peripheral blood	not available	female	Multiple Myeloma	not available	B lymphocyte	KMS-11	no compound	glycosylation	3	cell	run 363	proteomic profiling by mass spectrometry	UM_A_2013_0250_a3-KMS11.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0250_a3-KMS11.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-11	no compound
Sample 122	Homo sapiens	peripheral blood	61Y	male	plasmacytoma	not available	B lymphocyte	RPMI 8226	no compound	glycosylation	3	cell	run 364	proteomic profiling by mass spectrometry	UM_A_2013_0252_a1-RPMI8226.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0252_a1-RPMI8226.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	RPMI 8226	no compound
Sample 122	Homo sapiens	peripheral blood	61Y	male	plasmacytoma	not available	B lymphocyte	RPMI 8226	no compound	glycosylation	3	cell	run 365	proteomic profiling by mass spectrometry	UM_A_2013_0252_a2-RPMI8226.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0252_a2-RPMI8226.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	RPMI 8226	no compound
Sample 122	Homo sapiens	peripheral blood	61Y	male	plasmacytoma	not available	B lymphocyte	RPMI 8226	no compound	glycosylation	3	cell	run 366	proteomic profiling by mass spectrometry	UM_A_2013_0252_a3-RPMI8226.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0252_a3-RPMI8226.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	RPMI 8226	no compound
Sample 123	Homo sapiens	peripheral blood	64Y	female	Multiple Myeloma	not available	B lymphocyte	KMS-12	no compound	glycosylation	1	cell	run 367	proteomic profiling by mass spectrometry	UM_A_2013_0255_a1-KMS12.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0255_a1-KMS12.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-12	no compound
Sample 123	Homo sapiens	peripheral blood	64Y	female	Multiple Myeloma	not available	B lymphocyte	KMS-12	no compound	glycosylation	1	cell	run 368	proteomic profiling by mass spectrometry	UM_A_2013_0255_a2-KMS12.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0255_a2-KMS12.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-12	no compound
Sample 123	Homo sapiens	peripheral blood	64Y	female	Multiple Myeloma	not available	B lymphocyte	KMS-12	no compound	glycosylation	1	cell	run 369	proteomic profiling by mass spectrometry	UM_A_2013_0255_a3-KMS12.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0255_a3-KMS12.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-12	no compound
Sample 124	Homo sapiens	peripheral blood	64Y	female	Multiple Myeloma	not available	B lymphocyte	KMS-12	no compound	glycosylation	2	cell	run 370	proteomic profiling by mass spectrometry	UM_A_2013_0787_a1-KMS12.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0787_a1-KMS12.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-12	no compound
Sample 124	Homo sapiens	peripheral blood	64Y	female	Multiple Myeloma	not available	B lymphocyte	KMS-12	no compound	glycosylation	2	cell	run 371	proteomic profiling by mass spectrometry	UM_A_2013_0787_a2-KMS12.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0787_a2-KMS12.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-12	no compound
Sample 124	Homo sapiens	peripheral blood	64Y	female	Multiple Myeloma	not available	B lymphocyte	KMS-12	no compound	glycosylation	2	cell	run 372	proteomic profiling by mass spectrometry	UM_A_2013_0787_a3-KMS12.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0787_a3-KMS12.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-12	no compound
Sample 125	Homo sapiens	peripheral blood	53Y	male	plasmacytoma	not available	B lymphocyte	U266	no compound	glycosylation	1	cell	run 373	proteomic profiling by mass spectrometry	UM_A_2013_0788_a1-U266.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0788_a1-U266.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	U266	no compound
Sample 125	Homo sapiens	peripheral blood	53Y	male	plasmacytoma	not available	B lymphocyte	U266	no compound	glycosylation	1	cell	run 374	proteomic profiling by mass spectrometry	UM_A_2013_0788_a2-U266.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0788_a2-U266.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	U266	no compound
Sample 125	Homo sapiens	peripheral blood	53Y	male	plasmacytoma	not available	B lymphocyte	U266	no compound	glycosylation	1	cell	run 375	proteomic profiling by mass spectrometry	UM_A_2013_0788_a3-U266.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0788_a3-U266.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	U266	no compound
Sample 126	Homo sapiens	peripheral blood	64Y	female	Multiple Myeloma	not available	B lymphocyte	KMS-12	no compound	glycosylation	3	cell	run 376	proteomic profiling by mass spectrometry	UM_A_2013_0978_a1-KMS12.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0978_a1-KMS12.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-12	no compound
Sample 126	Homo sapiens	peripheral blood	64Y	female	Multiple Myeloma	not available	B lymphocyte	KMS-12	no compound	glycosylation	3	cell	run 377	proteomic profiling by mass spectrometry	UM_A_2013_0978_a2-KMS12.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0978_a2-KMS12.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-12	no compound
Sample 126	Homo sapiens	peripheral blood	64Y	female	Multiple Myeloma	not available	B lymphocyte	KMS-12	no compound	glycosylation	3	cell	run 378	proteomic profiling by mass spectrometry	UM_A_2013_0978_a3-KMS12.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0978_a3-KMS12.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	KMS-12	no compound
Sample 127	Homo sapiens	peripheral blood	53Y	male	plasmacytoma	not available	B lymphocyte	U266	no compound	glycosylation	2	cell	run 379	proteomic profiling by mass spectrometry	UM_A_2013_0979_a1-U266.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0979_a1-U266.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	U266	no compound
Sample 127	Homo sapiens	peripheral blood	53Y	male	plasmacytoma	not available	B lymphocyte	U266	no compound	glycosylation	2	cell	run 380	proteomic profiling by mass spectrometry	UM_A_2013_0979_a2-U266.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0979_a2-U266.mzXML	2	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	U266	no compound
Sample 127	Homo sapiens	peripheral blood	53Y	male	plasmacytoma	not available	B lymphocyte	U266	no compound	glycosylation	2	cell	run 381	proteomic profiling by mass spectrometry	UM_A_2013_0979_a3-U266.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0979_a3-U266.mzXML	3	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	U266	no compound
Sample 128	Homo sapiens	peripheral blood	53Y	male	plasmacytoma	not available	B lymphocyte	U266	no compound	glycosylation	3	cell	run 382	proteomic profiling by mass spectrometry	UM_A_2013_0980_a1-U266.mzXML	https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/06/PXD003469/UM_A_2013_0980_a1-U266.mzXML	1	1	AC=MS:1002038;NT=label free sample	NT=Trypsin;AC=MS:1001251	NT=LTQ Orbitrap XL;AC=MS:1000556	NT=Oxidation;MT=variable;TA=M;AC=UNIMOD:35	NT=Carbamidomethyl;TA=C;MT=variable;AC=UNIMOD:4	NT=Asn->Asp;AC=UNIMOD:621;MT=variable;TA=N	NT=collision-induced dissociation;AC=MS:1000133	35% NCE	50 ppm	0.8 Da	U266	no compound